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Harnessing Calcium Signaling in Dendritic Cells – A Potential Approach to Modulate the 
Immune Response In Vivo for Immunotherapy 
Abstract 
Over the past several decades, our understanding of the immune system has advanced 
considerably. With it, an appreciation for its role in a number of diseases, such as cancer and infection 
has significantly grown. While our increased understanding of the immunological mechanisms 
underlying these diseases has improved treatment, considerable morbidity and mortality from these 
illnesses still exists signifying the need for more effective and innovative therapies. Dendritic cell (DC) 
therapy has been shown to be a promising approach to induce strong immune responses for 
immunotherapy, and biomaterial-based strategies have been developed to target DCs in vivo to 
facilitate this purpose. Given the importance of calcium in DC function and activation, we hypothesized 
that we could develop a biomaterial-based approach to locally and specifically control calcium signaling 
in DCs in vivo as a novel strategy for immunotherapy. Our first sub-hypothesis was that the calcium used 
to crosslink alginate gels, a commonly used biomaterial, could activate DCs in vitro; our second sub-
hypothesis was that calcium ionophore A23187 could be delivered from biomaterials to activate DCs in 
vitro; and our third sub-hypothesis was that calcium used to crosslink alginate gels and/or controlled 
delivery of A23187 could increase local inflammation in vivo. We found that both the calcium released 
from calcium alginate gels and A23187 matured DCs and enhanced TLR-induced inflammatory cytokine 
secretion in vitro. Although we were unable to effectively deliver A23187 in vivo, calcium alginate gels 
injected subcutaneously were able to upregulate a number of inflammatory cytokines and chemokines 
relative to barium alginate gels. Likewise, when LPS was delivered from calcium alginate gels, the 
inflammatory effects of LPS on surrounding tissue were enhanced compared to when it was delivered 
from barium alginate gels. Thus, we confirmed that the calcium crosslinker in alginate gels could activate 
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DCs, and provided a proof-of-principle that calcium signaling could be harnessed in vivo to enhance the 
immune response. Not only does this work impact the future of biomaterial design, but it may also 
enhance our understanding of DC biology. This thesis lays the groundwork for a novel and potentially 
effective strategy for enhancing DC activation in vivo, and suggests that ion signaling pathways in other 
cell types (both immune and non-immune) could also be targeted using biomaterials.
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Chapter 1 
Calcium Signaling as a Potential Dendritic Cell Target for Immunotherapy 
 
 
1.1 Background and Motivation  
The Role of Dendritic Cells in Immunity 
Dendritic cells (DCs) are white blood cells that are of significant interest in the field of medicine 
because they link the innate and adaptive immune systems and help dictate final immune responses 
towards specific antigens [1]. As professional antigen presenting cells (APCs),  DCs reside in peripheral 
tissues where they continuously sample the environment and detect danger signals like those from 
invading pathogens (e.g. bacterial lipopolysaccharide (LPS), flagellin, unmethylated CpG DNA, double-
stranded RNA, etc.) or those from damaged tissues (e.g. heat shock proteins, extracellular ATP, uric acid, 
cholesterol crystals, etc.) [2-4]. Non-microbial exogenous matter, such as asbestos and aluminum 
hydroxide (alum), can also act as threats [5, 6]. When naïve DCs become activated by these warning 
indicators, they home to the lymph nodes where they present three critical signals to T cells to trigger an 
adaptive immune response (Figure 1.1A) [2, 7]. Signal 1 is antigen presented on major histocompatibility 
complex (MHC) class II, a cell-surface molecule that binds to antigen-specific T cell receptors (TCRs); 
Signal 2 is a co-stimulatory signal, such as B7.1 (CD80) or B7.2 (CD86), which are cell surface molecules 
upregulated during DC activation; lastly, Signal 3 is a soluble signal, such as secreted cytokines, which 
play an important role in skewing the T cell response. For example, inflammatory cytokines, such as IL-
12p70 and IFN-γ, drive naïve T cells towards a T-helper cell 1 (TH1) phenotype (important for combating 
viruses and bacteria), whereas anti-inflammatory cytokines, such as TGF-β and IL-10, can drive naïve T 
cells to differentiate into a T regulatory (Treg) phenotype (important for tolerogenic responses and 
suppressing inflammation) [2, 7, 8]. Figure 1.1B illustrates various cytokine-induced effector T cell 
responses.  
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Figure 1.1: APCs deliver three important signals to naïve T cells. (A) Signal 1 is antigen bound to MHC class II; 
Signal 2 is a co-stimulatory signal, such as B7.1 (CD80) or B7.2 (CD86); lastly, Signal 3 is a soluble signal, such as 
secreted cytokines. (B) Signal 3 dictates inflammatory (TH17/ TH1/TH2) or anti-inflammatory responses (Treg/TH3). 
Figures reproduced from [2]. 
 
 
Generally, the cytokine milieu expressed by DCs is dependent on the stimuli it encounters. 
Bacterial-derived signals, such as CpG DNA oligonucleotides, bind to toll-like receptors (TLRs) to promote 
TH1 cytokines [9], whereas helminth antigens, such as soluble egg glycans bind to TLR4 to promote TH2 
cytokines [10]. Although our understanding of regulatory responses is not as well-understood, vitamin D 
and thymic stromal lymphopoietin (TSLP) have been found to induce tolerogenic DCs [11, 12].  
A 
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In addition to external stimulatory signals controlling DC fate, certain DC subsets are intrinsically 
better at performing distinct functions [13, 14]. For instance, plasmacytoid DCs specialize in secreting 
type I interferons, which are critical for combating viral infections, while CD8+DEC205+ splenic DCs are 
better at cross-presenting antigens than other subsets [15]. Cross-presentation occurs when DCs uptake 
extracellular antigens, but rather than presenting them on MHC class II molecules, they present them on 
MHC class I molecules, which is important for activating cytotoxic T cells. Because DCs can be directed to 
initiate such diverse immune responses, they are popular therapeutic targets for immunotherapy. 
 
Ca2+ Regulation of Dendritic Cells 
Dendritic cells are highly dependent on Ca2+ to carry out their effector functions [16, 17]. While 
the Ca2+ concentration in the blood is approximately 2 mM, resting cells are able to maintain cytosolic 
Ca2+ concentrations of 10-100 nM by sequestering Ca2+ in organelles and employing ATP-driven Ca2+ 
pumps to pump Ca2+ against steep electrochemical gradients. When DCs encounter a stimulus, a rapid 
increase in cytosolic Ca2+ occurs [16, 17]. The exact mechanism of this Ca2+ spike is unclear, but it is 
thought that the stimulus activates tyrosine kinases and G-proteins, which trigger the formation of 1,4,5 
inositol triphosphate (IP3), a soluble molecule whose main function is to mobilize Ca2+ from organelles 
[16]. IP3 binds to IP3 receptors on the surface of organelles, such as the endoplasmic reticulum (ER), 
leading to the release of Ca2+ stores (Figure 1.2). In addition to IP3, the phosphorylation of sphingosine 
to yield sphingosine-1-phosphate (S1P) has also been implicated in the release of Ca2+ from the ER [16].  
When the ER becomes depleted of Ca2+, Ca2+- release activated current (CRAC) channels in the 
plasma membrane are activated causing an influx of extracellular calcium to replenish intracellular 
stores [17-19]. In turn, these large increases in cytosolic calcium activate several intracellular Ca2+-
sensing and -signaling molecules, which have been identified as having critical roles in DC activation and 
antigen presentation [16, 17]. For instance, when calmodulin (CaM), a Ca2+-sensing protein, binds Ca2+, it 
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can activate calcineurin and calcium-calmodulin dependent protein kinase II (CaMKII), which then 
activate transcription factors such as nuclear factor of activated T cells (NFAT) and nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB), respectively (Figure 1.2) [16, 17]. In DCs, these 
transcription factors lead to the synthesis of pro-inflammatory cytokines and co-stimulatory molecules 
such as CD80 and CD86. Additionally, studies demonstrate that the Ca2+-CaM-CaMKII signaling pathway 
is essential for phagosome maturation [16].  
 
Figure 1.2: The role of calcium in dendritic cell activation. Stimuli bind to receptors that initiate signaling 
pathways leading to the release of Ca2+ from intracellular stores, such as the ER, and subsequently the influx of 
extracellular Ca2+ into the cell. Increases in cytosolic Ca2+ activate calcineurin and CaMKII leading to the activation 
of transcription factors, such as NF-κB and NFAT, and the synthesis of inflammatory molecules. P2YR, 
metabotropic purinoceptor; P2X, purinoceptor; RyR, ryanodine receptor; TRPM4, transient receptor potential 
melastatin channel. Figure reproduced from [17]. 
 
Typically, stimulation with danger signals such as LPS activates signaling pathways leading to 
increased cytosolic Ca2+ and DC maturation [17, 20], but strikingly, it has been shown that simply raising 
intracellular calcium levels using calcium ionophores in the absence of danger signals is enough to 
differentiate dendritic cells and other myeloid cells into a mature DC phenotype [21, 22]. In addition to 
intracellular Ca2+-sensing proteins, the G-protein-coupled extracellular calcium-sensing receptor (CaR) 
has been implicated in the regulation of many cellular functions such as chemotaxis, apoptosis, 
proliferation, differentiation and ion-channel activity [23]. CaR can relay information about the local 
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extracellular Ca2+ concentration to the interior of the cell by activating the formation of IP3 and has been 
associated with the activation of several mitogen-activated protein kinases (MAPKs), which play 
important roles in DC activation [23, 24]. Given the importance of Ca2+ signaling in DC function, it could 
be a strong therapeutic target. 
 
Dendritic Cell-Based Immunotherapy 
Dendritic cells were first discovered in 1973, and since then, research studying and exploiting 
DCs for immunotherapy has quickly grown [1, 25]. The first clinical study examining the efficacy of 
autologous dendritic cell therapy was conducted in the mid-1990s [26]. In this study, DCs were isolated 
from lymphoma patients, pulsed ex vivo with B cell lymphoma antigens, and injected back into the 
patients to induce anti-tumor T cell responses [27]. Although these initial trials were unsuccessful, a 
number of studies have been conducted since then that have had more promising outcomes due to 
improved ex vivo antigen loading and DC maturation protocols, such as using GM-CSF or monocyte-
conditioned medium [28, 29]. DC therapy has also expanded to target many different types of cancers 
including melanoma, renal cell carcinoma, and leukemia [30, 31]. In 2010, the FDA approved the first ex 
vivo DC-based vaccine, Provenge, to treat prostate cancer [32].  
In addition to cancer vaccination, DCs are currently being tested for their ability to induce 
antigen-specific tolerogenic responses to treat autoimmunity and transplant rejection [33, 34]. Recently, 
a phase I study of autologous tolerogenic DC therapy was conducted to treat type I diabetes [35]. To 
generate an immunosuppressive phenotype, Signal 2 was knocked down by incubating DCs with 
phosphorothioate-modified antisense oligonucleotides targeting the 5' end of CD40, CD80 and CD86 
gene primary transcripts. Although DCs were safely tolerated, only minimal effects were observed, 
indicating the need for more improved protocols in this area. 
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Despite advances in ex vivo therapy, it is expensive, labor-intensive, and difficult to isolate 
sufficient numbers of DCs to be cultured in vitro [26]. Furthermore, there is significant cell death, short 
signal duration, and poor distribution when these cells are re-injected into the patient [1, 26]. To 
address these limitations, scientists and engineers are developing novel methods to target antigens and 
adjuvants directly to DCs in vivo. Earlier strategies included fusing antigens to monoclonal antibodies 
specific for DC receptors, such as DEC-205 and DC-SIGN, or to TLR agonists, such as CpG, which could 
then be injected into the patient [36]. More recently, biomaterials have been integrated into 
immunotherapies because they can act as adjuvants themselves, they can sustain the delivery of 
multiple immune modulators and antigens leading to long-term, durable immune responses, and they 
can target specific organs, white blood cell types, and subcellular compartments [37-39].  
One biomaterial-based approach is to implant porous polymer scaffolds to recruit and program 
DCs (Figure 1.3A) [40]. Poly(lactic-co glycolic acid) (PLG) scaffolds have been developed, which contain 
GM-CSF as a DC recruiting factor, CpG DNA as an adjuvant, and tumor lysates as an antigen source [41-
43]. An injectable formulation made of covalently crosslinked alginate also has been recently developed. 
In animal studies, these scaffolds have been inserted subcutaneously to successfully create infection-
mimicking niches that activate immune responses leading to the reduction of tumors.  
Due to their versatility, nanoparticles are also widely studied in the field of immunoengineering. 
Nanoparticles can be modified to bind to a variety of DC receptors and can also target DC subsets based 
on size [44, 45]. Not only can they transport antigens and adjuvants to specific sites in the body, such as 
the lymph nodes and mucosal tissues, but they can be designed to target subcellular compartments, 
such as the cytoplasm or endosomes (Figure 1.3B) [39].  Nanoparticles have been fabricated using a 
number of materials, such as synthetic polymers, lipids, hydroxyapatite, silica, gold, and iron-oxide [46]. 
Most nanoparticle strategies are still in preclinical stages but seem very promising as they have been 
shown to induce strong and systemic immune responses [37-39]. 
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Figure 1.3: Biomaterial-based strategies for immunotherapy. (A) Scaffolds containing chemoattractants, danger 
signals, and antigens can recruit and program DCs for immunotherapy. Figure adapted from [40]. (B) Nanoparticles 
encapsulating antigen or displaying surface-bound antigen can be targeted to DCs by conjugating the nanoparticles 
with targeting antibodies or ligands that bind to DC-specific receptors. Figure adapted from [44].
A 
 
B 
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Motivation 
Although our increased understanding of the immunological mechanisms underlying many 
diseases, such as cancer and infectious diseases, has led to strides in vaccination and immunotherapy, 
suffering and mortality from these illnesses still exceeds tens of millions signifying the need for more 
effective and novel treatments [47]. Given the impact and versatility of DCs in medicine, the potent 
effect that calcium has on DC activation, and the development of new biomaterial-based strategies to 
target DCs, we propose that one could use biomaterials to specifically target and enhance calcium 
signaling in DCs in vivo as a means to activate them for immunotherapy. To date, we have not found a 
study examining this. We developed one main hypothesis and three sub-hypotheses based on this 
concept, and they are outlined below. 
 
1.2 Hypotheses and Aims 
Main Hypothesis 
A biomaterial-based approach can be developed to locally enhance calcium signaling in DCs in 
vivo as a strategy to boost their activation for immunotherapy.  
 
Sub-Hypothesis 1 
Calcium used to crosslink alginate gels, a commonly used biomaterial, can promote DC 
activation in vitro.   
 Aim 1: Examine the effect of calcium-crosslinked alginate and other biomaterials on DC 
activation in vitro. 
Aim 2: Determine if any differences between the materials are due to the polymer components 
of the materials and/or the calcium used to crosslink the alginate gels. 
 
 9 
 
Sub-Hypothesis 2 
Calcium ionophore A23187, a small molecule that increases intracellular calcium, can be 
delivered from biomaterials to activate DCs in vitro.  
Aim 1: Test if A23187 can promote inflammatory cytokine secretion, co-stimulatory molecule 
expression and antigen presentation in vitro. 
Aim 2: Test if A23187 can be delivered from biomaterials to activate DCs in vitro. 
 
Sub-Hypothesis 3 
Calcium used to crosslink alginate gels and/or controlled delivery of A23187 can increase local 
inflammation in vivo. 
Aim 1: Determine if calcium-crosslinked alginate gels injected into mice can promote 
inflammatory cytokine secretion from surrounding tissue. 
 Aim 2: Test whether A23187 can be delivered from biomaterials to also promote local 
inflammatory cytokine secretion. 
 
1.3 Thesis Outline 
 The next chapters describe the experiments performed to test the above hypotheses. Chapter 2 
tests Sub-Hypothesis 1 (addressing Aims 1 and 2), Chapter 3 tests Sub-Hypothesis 2 (addressing Aims 1 
and 2), and Chapter 4 tests Sub-Hypothesis 3 (addressing Aims 1 and 2). Chapter 5, the final chapter, 
discusses the conclusions, implications, and future directions of this work. 
 
1.4 Significance 
It is widely appreciated that Ca2+ is one of the most versatile second messengers in white blood 
cell signaling with important roles in transcription, apoptosis, cell adherence, activation, exocytosis, 
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metabolism and proliferation [18, 20, 48]. As discussed above, dendritic cells require Ca2+ signaling for 
cytokine secretion, maturation marker expression, and phagocytosis [16, 17]. This thesis proposes a 
unique way to enhance the immune response by exploiting calcium signaling in dendritic cells in vivo, 
and suggests that ion signaling pathways in other cell types (both immune and non-immune) could also 
be targeted using biomaterials.  
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Chapter 2 
Effect of Calcium Alginate Gels on Dendritic Cells In Vitro 
 
2.1 Introduction 
Alginate, also known as alginic acid, is an anionic, linear and unbranched polysaccharide isolated 
from algae or bacterial biofilms. Alginate is composed of (1, 4)-linked, β-D-mannuronate (M) and α-L-
guluronate (G) sugar monomers that are arranged in M blocks (MMMMMM), G blocks (GGGGGG), or 
alternating M and G residues (MGMGMG), with the exact M and G composition being dependent on the 
algae or bacteria source. Alginate polymers have a high affinity for divalent cations (in the order Mg2+<< 
Ca2+ < Sr2+ < Ba2+) and can form a crosslinked network when these divalent cations associate with the G 
blocks in a proposed “egg-box” model to form crosslinks between the polymer chains (Figure 2.1) [1, 2]. 
Thus, alginate polymers rich in G blocks are able to create more crosslinks and stiffer gels [1, 3]. 
 
Figure 2.1: Ca2+ binds to the G blocks of alginate in a proposed “egg-box” leading to crosslinking of the polymer. 
Adapted from [1]. 
 
In physiological buffers, such as PBS, cell culture medium, or serum, monovalent cations (e.g. 
Na+) compete with divalent cations crosslinking the alginate, which causes the release of crosslinker and 
weakening of the gel over time [4]. Because calcium-crosslinked alginate (calcium alginate) hydrogels 
are considered biocompatible, can encapsulate cells, drugs, and bioactive factors under physiological 
conditions, and can be tailored to have different mechanical properties and dissolution/degradation 
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rates depending on the M and G ratio, the molecular weight of the alginate, and the type and 
concentration of crosslinker used, they are widely used in tissue engineering and drug delivery [5-7]. 
Based on the importance of calcium signaling in white blood cell activation, we hypothesized 
that the calcium released from calcium alginate gels could mature and enhance the activation of DCs, 
which are highly sensitive to calcium. Despite calcium alginate’s common use for biomedical purposes, 
we could not find a study examining the effects of calcium on leukocytes exposed to calcium alginate 
gels, even in studies where DCs were encapsulated in calcium-crosslinked alginate gels for 
immunotherapy [8, 9]. Contrary to this, the inflammatory properties of alginate polymers have been 
widely studied and disputed. For example, dissolved alginate polysaccharides (100-1000 µg/ml) have 
been shown to activate monocytes and macrophages depending on the molecular weight and the M and 
G ratio of the polymer [10, 11]. However, other studies have shown that alginate can actually suppress 
inflammatory disease [12] or have demonstrated no effect at all [13].  
In the following study, calcium alginate was tested against three commonly used biomaterials 
(agarose, collagen and tissue culture polystyrene (TCPS)) for its ability to induce DC maturation and/or 
affect LPS-induced activation. The impact of both the alginate polymer itself and the calcium used to 
crosslink the alginate gels were assessed. To evaluate the immunostimulatory effects of alginate gels, 
DCs were cultured within alginate gels as well as externally in the presence of alginate gels. The 
cytokines IL-1β, IL-4, IL-6, IL-10, IL-12p70, IFN-γ and TNF-α and the activation markers CD86 and MHC 
class II were analyzed to gauge DC maturation.  
 
2.2 Materials and Methods 
Cell Culture 
Dendritic cells were generated from bone marrow isolated from 4-16 week old C57BL/6J mice 
(Jackson Laboratory, Bar Harbor, ME) as described by Lutz et al [14]. On Day 0, mice were sacrificed and 
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their femurs and tibias removed. The bones were stripped of muscle and tendon with sterile scissors 
and washed three times in 10 ml of Hank’s Balanced Salt Solution (HBSS) (Life Technologies, Carlsbad, 
CA) without calcium or magnesium and containing 1500 U/ml penicillin and 1500 µg/ml streptomycin 
(Life Technologies). The ends of the bones were cut and the marrow was flushed into a Petri dish using a 
23 or 25 gauge needle and 10 ml syringe containing 10 ml of HBSS with 2% heat-inactivated FBS (Sigma-
Aldrich, St. Louis, MO) and 1% 1 M HEPES buffer solution (Life Technologies). The bone marrow was 
then broken up with vigorous pipetting using a syringe and 18 gauge needle. The cells were passed 
through a 70 µm cell strainer and counted with a Z2 Coulter Counter (Beckman Coulter, Brea, CA) 
using a range of 5 to 17 µm to exclude erythrocytes. Without lysing erythrocytes, 2x106 cells were plated 
per 100x15 mm non-tissue culture treated Petri dish (BD Falcon, Franklin Lakes, NJ) in 10 ml of R10 
medium (RPMI-1640 medium (Sigma-Aldrich) containing 2 mM L-glutamine, 10% heat-inactivated FBS, 
100 U/ml penicillin, 100 µg/ml streptomycin, 50 µm of β-mercaptoethanol (Sigma-Aldrich) and 200 U/ml 
rmGM-CSF (PeproTech, Rocky Hill, NJ)). On Day 3, 10 ml of fresh R10 was added to each plate to bring 
the final volume to 20 ml. On Days 6, 8 and 10, 10 ml of medium were removed and centrifuged; the cell 
pellet was then resuspended in 10 ml of fresh medium and added back to culture. For experiments, only 
non-adherent cells between Days 8 and 12 were used, and the rmGM-CSF concentration was dropped to 
100 U/ml. The non-adherent DCs generated with this protocol were determined to be greater than 90% 
CD11c positive by flow cytometry.  
 
Endotoxin Testing 
All polymer solutions, calcium crosslinkers and other ion-supplemented solutions used in this 
study were tested using the Limulus Amebocyte Lysate (LAL) Assay (Lonza, Walkersville, MD) according 
to the manufacturer’s instructions. 
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Comparing DC Activation across TCPS, Collagen, Agarose and Alginate Gels 
Cell-Seeding on TCPS 
For TCPS conditions, DCs were plated at a concentration of 250,000 cells/100 µl PBS/well of a 
48-well plate and incubated at 37°C for 30 minutes. 
 
Collagen Gel Fabrication 
Rat tail collagen, type I (BD Biosciences, Franklin Lakes, NJ) was certified to be negative for 
bacteria, fungi and mycoplasma and used without further purification. DCs were harvested, washed 
once in PBS, and resuspended at a concentration of 10x106 cells/ml in a 3 mg/ml ice cold collagen 
solution prepared aseptically according to the manufacturer’s instructions.  100 µl (106 cells) were 
pipetted into the wells of a 48-well plate and allowed to cure at 37°C for 30 minutes.   
 
Agarose Gel Fabrication 
A 1.2% SeaPlaque agarose solution (Lonza, Allendale, NJ) in PBS was sterilized by autoclaving. 
For cell encapsulation, the solution was microwaved until fully dissolved. After cooling to 40°C in a water 
bath, DCs were resuspended in agarose at a concentration of 10x106 cells/ml, and 100 µl (106 cells) were 
immediately pipetted into the wells of a 48-well plate. The agarose quickly cured at room temperature 
and was placed at 37°C for 30 minutes.   
 
Alginate Gel Fabrication 
PRONOVA™ Ultrapure medium viscosity alginate rich in α-L-guluronate residues (MVG) (FMC 
BioPolymer, Sandvika, Norway) was certified to be free of yeast, mold and bacteria and have an 
endotoxin content ≤100 EU/g. MVG alginate was further sterilized by dissolving it in deionized water and 
filtering it through a 0.22 µM pore diameter membrane (Millipore, Billerica, MA). The sterile alginate 
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solution was frozen, lyophilized and reconstituted aseptically in PBS to make a 2% solution. A 
CaSO4∙2H2O slurry (183 mM) in deionized water was sterilized by autoclaving. DCs in PBS were mixed 
with the 2% alginate solution using two 1 ml syringes connected with a nylon female luer thread style 
coupler (Value Plastics, Fort Collins, CO) for a final concentration of 13x106 cells/ml. 78 µl (106cells) of 
this suspension was added to wells of a 48-well plate using an 18 gauge needle, and 22 µl of thoroughly 
mixed CaSO4 slurry was quickly pipetted and stirred into the alginate in each well. The alginate was 
allowed to cure at 37°C for 30 minutes. Final alginate gels contained 1.2% alginate, 40 mM CaSO4, and 
106 cells in a 100 µl gel volume. 
 
DC Activation 
After DC plating and encapsulation in hydrogels, 350 µl of R10 medium was added to each well 
and allowed to equilibrate at 37°C and 5% CO2 for 1 hour before activation. For activation, 50 µl of 1000 
ng/ml LPS (E. coli 0111:B4; Sigma-Aldrich) in R10 was added to each well so that the final concentration 
was 100 ng/ml; for LPS-free wells, 50 µl of R10 only was added. After 20-24 hours of activation on an 
orbital shaker, supernatant was collected and frozen at -20°C for cytokine analysis. For cytokine analysis, 
see below. 
 
Soluble Polymer Studies with Collagen, Agarose and Alginate 
Sterile 1 mg/ml solutions of dissolved collagen, agarose and alginate were made in PBS. In 
addition to the polymers used for gel fabrication, additional alginate polymers tested included pure G 
and β-D–mannuronate (M) blocks (provided by Dr. Kamal Bouhadir at the American University of Beirut, 
Lebanon) and PRONOVA™ Ultrapure medium viscosity (MV), low viscosity (LV) and very low viscosity 
(VLV) alginates rich in either G or M residues (FMC BioPolymer). Each polymer solution was then diluted 
1:10 in R10 medium for a final concentration of 100 µg/ml (referred to as polymer R10). PBS was used 
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for the control. To prevent any potential differences in protein adsorption from affecting cell 
attachment across the different conditions, 200 µl of R10 medium was added to wells of a 96-well plate 
and incubated overnight to coat the wells with serum proteins prior to cell plating. DCs were harvested, 
washed in PBS, resuspended in the 100 µg/ml polymer solutions above, and plated at a density of 
100,000 cells/180 µl/ serum-coated well. After 1 hour of incubation at 37°C and 5% CO2, cells were 
stimulated with 20 µl of 1000 ng/ml LPS in basal R10 or polymer R10 to give a final concentration of 100 
ng/ml; for LPS-free wells, 20 µl of basal R10 or polymer R10 only was added. After 20-24 hours, 
supernatant was collected and frozen at -20°C for cytokine analysis. 
 
Calcium Studies on TCPS 
Sterile, high calcium-containing medium was made by adding CaCl2∙2H2O to deionized water, 
filtering it through a 0.22 µM membrane, and diluting it 1:100 in R10 so that the final calcium 
concentration equaled 3, 6 or 12 mM (basal R10=0.42 mM). Sterile deionized water was used for the 
control. To determine whether results were calcium-specific, magnesium, potassium and sodium ions 
were also screened for their ability to alter cytokine expression. Medium was supplemented with each 
ion so that its final concentration (Ca=3 mM; Mg=1 mM; K=5.6 mM, Na=162 mM) was 10% higher than 
the physiological upper limit; the calcium ionophore A23187 (400 ng/ml) (Sigma-Aldrich), which 
increases cytosolic calcium, was used as a positive control. DCs were harvested, washed once in PBS, 
and resuspended in basal medium or R10 containing high calcium, magnesium, potassium, sodium or 
A23187 (referred to as high ion R10). For cytokine analysis, 100,000 cells/180 µl of basal or high ion R10 
were plated per well of a 96-well plate and allowed to equilibrate at 37°C and 5% CO2. After 1 hour, 20 
µl of 1000 ng/ml LPS in basal or high ion R10 was added to each well for a final concentration of 100 
ng/ml; for LPS-free wells, 20 µl of basal or high ion R10 only was added. After 20-24 hours of activation 
supernatant was collected and frozen at -20°C. To measure surface marker expression, 106 cells/1.8 ml 
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basal or high calcium R10 were plated per well of a 6-well plate and stimulated with 200 µl of activation 
or LPS-free medium as above. Cytokines and cell-surface markers were detected and analyzed as 
described below. 
 
Comparing DC Activation in Alginate Gels with Varying Calcium Concentration 
Barium and Calcium Crosslinked Alginate Beads 
DCs were harvested, washed once in PBS, and resuspended in R10 at a concentration of 125x106 
cells/ml. 800 µl of a sterile 2.5% Ultrapure MVG alginate solution in PBS was mixed with 200 µl of cell 
suspension using two 5 ml syringes connected with a coupler to give a final concentration of 25x106 
cells/ml of 2% alginate. A sterile beaker containing a sterile 10 mM BaCl2 or 100 mM CaCl2 solution with 
0.1 M HEPES in ddH2O (pH 7.4) was stirred using a stir plate while the alginate was ejected into the bath 
using a 30 gauge needle to create uniform alginate beads ~2 mm in diameter (~4 µl volume) with 
~100,000 cells/bead. The beads were allowed to stir for 10 minutes for complete gelation, poured into a 
0.22 µM filter, and washed twice with 50 ml of PBS. Ten beads (~106 cells) were placed in each well of a 
48-well plate containing 500 µl medium and were allowed to equilibrate at 37°C and 5% CO2. After 1 
hour, 60 µl of 1000 ng/ml LPS in R10 was added so that the final concentration in each well was 100 
ng/ml; for LPS-free wells, 60 µl of R10 only was added. Beads were incubated on an orbital shaker for 
20-24 hours after which supernatant was collected and frozen at -20°C. For cytokine and cell-surface 
marker analysis, see below. 
 
10 and 100 mM CaCl2 Alginate Beads 
DCs were harvested, washed once in PBS, and resuspended in PBS at a concentration of 100x106 
cells/ml. 750 µl of a sterile 2% Ultrapure MVG alginate solution in R10 was mixed with 250 µl of cell 
suspension using two 5 ml syringes connected with a coupler to give a final concentration of 25x106 
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cells/ml of 1.5% alginate. A sterile beaker containing a sterile 10 or 100 mM CaCl2 solution with 0.1 M 
HEPES in ddH2O (pH 7.4) was stirred using a stir plate while the alginate was ejected into the CaCl2 bath 
using a 30 gauge needle to create uniform alginate beads ~2 mm in diameter (~4 µl volume) with 
~100,000 cells/bead. The beads were allowed to crosslink for 10 minutes and then were washed and 
cultured as above. 
 
10 and 40 mM CaSO4 Alginate Discs 
DCs were harvested, washed once in PBS, and resuspended in R10 at a concentration of 128x106 
cells/ml. 1.2 ml of a sterile 2% Ultrapure MVG alginate solution in R10 was mixed with 300 µl of cell 
suspension using two 3 ml syringes connected with a coupler. The syringe containing the alginate-cell 
suspension was then connected to a third syringe containing 420 µl of 183 or 46 mM CaSO4 crosslinker. 
The two syringes were pumped back and forth quickly 8-10 times to homogeneously mix the alginate 
with the crosslinker, and the mixture was cast between two Teflon-coated aluminum plates (McMaster-
Carr, Elmhurst, IL) with 1 mm spacers. The alginate was allowed to cure for 10-20 minutes, after which 8 
mm diameter discs were punched using a disposable biopsy punch (Premier, Plymouth Meeting, PA). 
Final discs were 8 x 1 mm (~50 µl) and contained 1.25% alginate, 106 cells, and either 10 or 40 mM 
CaSO4. Discs were placed in 490 µl R10 in 48-well plates and allowed to equilibrate at 37°C and 5% CO2. 
After 1 hour, 60 µl of 1000 ng/ml LPS in R10 was added so that the final concentration in each well was 
100 ng/ml; for LPS-free wells, 60 µl of R10 only was added. Discs were incubated on an orbital shaker for 
20-24 hours after which supernatant was collected and frozen at -20°C. For cytokine and cell-surface 
marker analysis, see below. 
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DCs Cultured in the Presence of Barium and Calcium Alginate Gels 
 For cytokine analysis, 106 DCs in 2 ml of medium were plated in 6-well plates. After 1 hour of 
culture, 200 µl of 4 mM barium- or 48.8 mM calcium-crosslinked alginate gels were added to wells. Gels 
were fabricated by mixing a 2.5% MVG alginate solution in R10 with 20 mM BaCl2 or 244 mM CaSO4 
crosslinker solution in water in a 4:1 ratio using two syringes connected by a coupler. 200 µl was ejected 
through an 18 gauge needle onto a sterile plate and allowed to cure for 10 minutes. Final gels, 
containing 2% alginate, were then added to wells using a sterile spatula. After 20-24 hours of stagnant 
culture, supernatants were collected for IL-1β analysis. For surface marker analysis, the above procedure 
was repeated except gels were cast between two Teflon-coated aluminum plates and 8 mm discs were 
punched using a biopsy punch. Four gels were added per well and DCs were cultured on an orbital 
shaker. After 20-24 hours, cells were scraped from wells for surface marker staining as described below. 
 
Cell-Surface Marker Analysis 
For studies on TCPS, 1 ml of 50 mM EDTA in PBS (pH 7.4) was added to each well, and plates 
were placed in the incubator for 15 minutes to aid in cell detachment. Cells were then scraped from 
wells and washed with stain buffer (BD Pharmingen, Franklin Lakes, NJ). To retrieve DCs from the gels, 
500 µl of 50 mM EDTA in PBS (pH 7.4) was added to each well. Gels were allowed to dissolve at 37°C and 
cells were collected and washed in stain buffer. Collected cells were stained with APC-conjugated anti-
mouse CD11c, FITC-conjugated anti-mouse MHC class II and PE-conjugated anti-mouse CD86 
(eBioscience, San Diego, CA). Cell-surface antigen staining was analyzed using an LSR II or LSR Fortessa™ 
flow cytometer (BD Biosciences). Cell viability was determined using SSC vs. FSC, and only viable cells 
were gated for surface marker analysis. 
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Cytokine Analysis 
Cell culture supernatants were analyzed for mIL-1β, mIL-4, mIL-6, mIL-10, mIL-12p70, mIFN-γ 
and mTNF-α using the Bio-Plex Pro™ Magnetic Cytokine Assay System (Bio-Rad, Hercules, CA).  
 
Calcium Release Assay 
Alginate beads and discs were fabricated and incubated in R10 as above but without cells. 
Medium was collected at 1, 4 and 10 hours, frozen at -20°C, and later assayed using the QuantiChrom™ 
Calcium Assay Kit (BioAssay Systems, Hayward, CA) according to the manufacturer’s instructions. R10 
alone was assayed as t=0. Briefly, 5 µl of thawed sample or standard was added to a 96-well plate 
followed by 200 µl of Quantichrom™ working solution. Samples were mixed by gently tapping the plate 
and incubated for 3 minutes at room temperature before absorbance was read at 612 nm with a 
Synergy™ HT microplate reader (Bio-Tek, Winooski, VT). 
 
Intracellular Calcium Assay 
To measure intracellular calcium, cells were labeled with the fluorescent intracellular calcium 
probe Fluo-4 AM (Life Technologies). DCs were harvested, washed in PBS, and resuspended at a density 
of 106 cells/ml in 5 µM Fluo-4 AM in PBS for 30 minutes at room temperature. Labeled cells were then 
washed in PBS and allowed to sit for another 30 minutes to allow for complete de-esterification of the 
probe before plating or encapsulation. Immediately after plating on TCPS or being encapsulated within 
alginate gels, cells were imaged with an EVOS fl microscope (AMG, Bothell, WA) using the FITC 
channel. For kinetic studies, DCs were plated on TCPS in increasing calcium concentrations as above and 
fluorescence was measured using a Synergy™ HT microplate reader (Ex. 488 nm, Em. 516) at multiple 
timepoints after plating. For all intracellular calcium studies, the anti-FITC antibody A889 (Life 
Technologies) was diluted in the medium 1:200 to quench background fluorescence. 
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Differential Interference Contrast (DIC) Microscopy and Photos of Whole Alginate Gels 
DIC images of cells were taken using an Olympus IX81 inverted microscope (Olympus, Center 
Valley, PA). Photos of whole alginate gels were taken with a Nikon COOLPIX p90 camera (Nikon, 
Melville, NY). 
 
Graphs and Statistical Analysis 
Flow cytometry data was analyzed and plotted using FlowJo software (Tree Star, Ashland, OR), 
and all other graphs were made using Kaleidagraph software (Synergy Software, Reading PA). 
Statistical analysis was performed using Microsoft Excel (Microsoft, Redmond, WA) or Kaleidagraph 
software. A two-tailed Student’s t-test assuming equal variances was used when comparing two groups, 
and a one-way analysis of variance (ANOVA) followed by a post-hoc Tukey test was used when 
comparing multiple groups. For all experiments n=3-4. Data is reported as the mean ± standard 
deviation. 
 
2.3 Results 
Endotoxin Testing 
 All polymer solutions, calcium crosslinkers and other ion-supplemented solutions used in this 
study tested ≤0.1 EU/ml. 
 
DC Comparison across Materials 
To determine if calcium-crosslinked alginate gels had a distinct effect on DC behavior, DCs 
encapsulated in CaSO4 alginate gels were compared to DCs encapsulated in agarose and collagen gels 
and DCs plated on TCPS. Agarose was chosen because like alginate, it is a polysaccharide that lacks 
integrin binding motifs and cannot be enzymatically degraded by mammalian cells; collagen and TCPS 
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were chosen as standard biomaterial controls. In order to cast DCs in alginate gels at the bottom of wells 
consistently with collagen and agarose gels, CaSO4 was used as the crosslinker because it is less soluble 
in aqueous solution than CaCl2 (a more commonly used calcium crosslinker) leading to a slower gelation 
rate and the ability to mold alginate gels in shapes other than rounded beads. CaSO4 precipitates were 
visible immediately after casting (Figure 2.2), but by 24 hours were no longer present due to the alginate 
gel binding free Ca2+ ions and allowing the precipitates to solubilize. DCs in alginate or agarose gels had a 
rounded appearance throughout the duration of the experiment, while cells on TCPS and in collagen 
were able to migrate, spread and make direct cell-cell contacts (Figure 2.2).  
 
Figure 2.2: Photomicrographs of DCs cultured on TCPS and encapsulated in various hydrogels. Photomicrographs 
were taken of DCs adhered to TCPS or encapsulated in collagen (COL), agarose (AGR) or alginate (ALG) gels one 
hour after encapsulation. 
 
To determine if there were differences in DC activation across the materials, cell culture 
supernatants were assayed for various inflammatory cytokines. DCs encapsulated in calcium-crosslinked 
alginate gels produced significantly higher levels of the inflammatory cytokine IL-1β when compared to 
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DCs encapsulated in agarose and collagen gels and DCs plated on TCPS (Figure 2.3). Overall cytokine 
expression increased for all conditions when cells were stimulated with LPS, but IL-1β was even further 
enhanced with alginate gels (Figure 2.3). Interestingly, with LPS stimulation, DCs in agarose gels 
produced significantly higher levels of TNF-α, while DCs plated on TCPS produced significantly higher 
levels of IL-6 (Figure 2.3). mIL-4 and mIFN-γ secretion were negligible for both LPS-free and LPS 
stimulated cells in all conditions and thus excluded from the rest of the study.  
 
Figure 2.3: Alginate gels enhanced IL-1β secretion from encapsulated DCs. DCs were cultured without LPS or with 
LPS. After 24 hours, supernatant was collected and analyzed for multiple cytokines. Asterisks indicate that the 
condition is significantly different from the other material being compared. *P≤0.05; **P≤0.001. 
 
The impact of each gel on soluble Ca2+ levels was next analyzed. As mentioned previously, in 
physiological buffers, such as PBS, cell culture medium, or serum, monovalent cations (e.g. Na+) 
compete with divalent cations crosslinking the alginate, which causes the divalent cations to be released 
over time. Over a 10 hour period, calcium-crosslinked alginate gels increased Ca2+ in the surrounding 
medium to approximately 5 mM (indicating that ~43% of the calcium initially incorporated into the gel 
was released), while the other gels did not impact the Ca2+ concentration (Figure 2.4). These results 
indicated that calcium-crosslinked alginate gels elevated extracellular calcium levels and had a unique 
effect on DC behavior and activation when compared to other materials.    
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Figure 2.4: Alginate gels released high levels of calcium. The Ca2+ released into medium from each of the 
hydrogels was quantified over 10 hours.  
 
 
Testing Polymer Components of Gels on TCPS-Cultured DCs 
The impact of the polymer components of the three hydrogels tested were next examined by 
culturing DCs on TCPS overnight with each of the three dissolved polymers. In the absence of LPS, IL-6 
secretion for alginate was slightly higher than the no polymer (NP) condition (Figure 2.5A), and in the 
presence of LPS, IL-1β and IL-12p70 secretion for collagen and agarose, respectively, were slightly 
different from NP (Figure 2.5A). However, these differences were minor and did not account for the 
trends seen with intact gels. Similarly, the various alginate polymers screened in Table 1 did not induce 
or enhance cytokine expression compared to NP (Figure 2.5B). 
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Figure 2.5 (Continued): Soluble polymer components of gels were not responsible for trends seen with intact 
gels. (A) DCs were cultured on TCPS with no polymer (NP), or dissolved collagen (COL), agarose (AGR) or alginate 
(ALG), in the absence of LPS or in the presence of LPS. After 24 hours, supernatant was collected and multiplexed 
for cytokines. (B) DCs were cultured on TCPS with dissolved alginate polymers of varying molecular weight and M 
and G ratio (see Table 1) in the absence of LPS or in the presence of LPS. After 24 hours, supernatant was collected 
and multiplexed for cytokines. Asterisks indicate that the polymer condition is significantly different from NP. 
*P≤0.05. 
 
 
Table 1: Molecular weight and M and G percentage of alginate polymers tested in Figure 2.5. 
 
 
 
Testing Calcium-Supplemented Medium on DCs Cultured on TCPS 
The impact of free Ca2+ on cytokine secretion was tested next. DCs were cultured on TCPS in 
medium supplemented with calcium up to 3, 6 or 12 mM. Interestingly, DCs extended longer processes 
as the calcium concentration in the medium increased, particularly for 12 mM calcium, and although LPS 
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stimulation caused cells to contract, the spindle-like morphology seen with 12 mM calcium was still 
apparent (Figure 2.6).  
 
Figure 2.6: DCs altered their morphology when cultured in increasing concentrations of calcium. 
Photomicrographs were taken of DCs cultured on TCPS in medium containing 0.42 mM calcium (basal) or 
supplemented with 3, 6, or 12 mM calcium in the absence or presence of LPS. 
 
Fluo-4, a fluorescent intracellular calcium probe, was used to quantify the levels of intracellular 
calcium for each of the calcium concentrations. Both photomicrographs and microplate readings 
revealed that the intracellular calcium levels rose with increasing extracellular calcium (Figure 2.7A and 
B). Although intracellular calcium concentrations were highest immediately after plating and fluctuated 
within the first hour, a sustained high intracellular Ca2+ concentration was observed and maintained for 
at least 10 hours (Figure 2.7B). 
 
 
 
 
 
       
 30 
 
                        
 
 
 
Figure 2.7: Intracellular calcium concentration positively correlated with extracellular calcium concentration. 
DCs were labeled with the intracellular calcium probe Fluo-4 and plated with increasing concentrations of calcium 
as above. (A) Cells were imaged immediately after plating (only 0.42 and 12 mM are shown) or (B) fluorescence 
was quantified over a 10 hour period using a plate reader. 
 
 
Despite the fact that DCs in the 3, 6 and 12 mM calcium conditions looked equally as viable as 
the 0.42 mM conditions, forward-side scatter analysis using flow cytometry revealed that high levels of 
calcium reduced cell viability in a dose-dependent manner and that LPS stimulation further reduced cell 
viability (Figure 2.8).  
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Figure 2.8: Increasing extracellular calcium and stimulating with LPS decreased cell viability. DCs were plated in 
increasing concentrations of calcium as above for 24 hours in the absence or presence of LPS. Cells were collected 
and viability was quantified based on forward-/side-scatter measurements obtained using flow cytometry. 
 
 
Analysis of cell culture supernatants showed that high levels of extracellular calcium led to an 
increase in IL-1β both with and without LPS stimulation (with secretion peaking at 3 mM calcium) 
(Figure 2.9). This data was consistent with DCs cultured in alginate gels. Interestingly, in the LPS-free 
condition, high levels of extracellular calcium also upregulated IL-6 and TNF-α secretion, but in the 
presence of LPS, had no effect on IL-6 and actually downregulated IL-12p70 and TNF-α (Figure 2.9).  
  
Figure 2.9: Supplementing medium with excess calcium induced IL-1β secretion. DCs were cultured in R10 
supplemented with increasing concentrations of calcium in the absence or presence of LPS. After 24 hours, 
supernatants were multiplexed for cytokines. Asterisks indicate that the calcium-supplemented condition is 
significantly different from the 0.42 mM (basal) condition. *P≤0.05; **P≤0.001. 
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To determine whether these trends were calcium-specific, and not due to an increase in 
osmolality, several physiologically relevant ions were screened for their ability to alter cytokine 
expression. R10 was supplemented with calcium, magnesium, sodium, or potassium so that the 
concentration of the ion was 10% higher than the physiological upper limit; the calcium ionophore 
A23187, which increases cytosolic calcium, was used as a positive control. The increase in IL-1β, IL-6 and 
TNF-α observed with calcium was repeated only with A23187, which demonstrated that the effect was 
specific to calcium (Figure 2.10).   
 
 
Figure 2.10: Cytokine secretion induced by excess calcium was calcium-specific. DCs were cultured on TCPS in 
medium supplemented with calcium, magnesium, potassium, or sodium at a concentration ~10% higher than the 
physiological upper limit. The calcium ionophore A23187 was tested as a positive control. After 24 hours, 
supernatants were collected and analyzed for cytokines. Asterisks indicate that the ion-supplemented condition is 
significantly different from the control condition. *P≤0.05; **P≤0.001. 
 
DCs cultured in increasing concentrations of calcium were stained with anti-CD86 and anti-MHC 
class II antibodies, and live cells were gated into populations of negative, low or high expression of each 
marker based on flow cytometry histograms (Figure 2.11A). In LPS-free medium, increasing extracellular 
calcium correlated with increasing MHC class IIhiCD86hi double-positive expression in a dose-dependent 
manner, while LPS stimulation caused MHC class IIhiCD86hi double-positive cells to plateau at 
approximately 80% across all calcium concentrations (Figure 2.11B). 
       
 
0
50
100
150
200
250
300
IL-1β IL-6 IL-10 IL-12 TNF-α
Control
Ca
Mg
K
Na
A23187
pg
/1
06
 c
el
ls
A
**
**
**
* **
**
 33 
 
 
 
Figure 2.11: Supplementing medium with excess calcium upregulated DC activation markers. DCs cultured in 
increasing concentrations of calcium, in the absence or presence of LPS, were detached from the TCPS, stained 
with PE-labeled anti-CD86 and FITC-labeled anti-MHC class II, and analyzed using flow cytometry. (A) Live cells 
were gated into negative (neg), low (lo), or high (hi) populations. Filled gray histograms are isotype controls. (B) 
The percentage of MHC class IIhiCD86hi double-positive cells were calculated based on neg/lo/hi gating. Asterisks 
indicate that the calcium-supplemented condition is significantly different from the basal (0.42 mM) condition. 
*P≤0.05; **P≤0.001.
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Testing Calcium Crosslinker in Alginate Gels 
Given evidence that it was the calcium crosslinker and not the alginate polymer accounting for 
enhanced DC maturation, we hypothesized that DCs encapsulated in calcium-crosslinked alginate would 
have a greater degree of maturation than DCs encapsulated in barium-crosslinked alginate. To test this, 
DCs were encapsulated in alginate droplets crosslinked in a 10 mM BaCl2 or 100 mM CaCl2 bath (the 
most standard method for crosslinking alginate) and analyzed for their ability to induce DC maturation. 
100 mM CaCl2 was chosen because it is a concentration typically used for biomedical applications, and 
10 mM BaCl2 was selected because it yielded beads approximately the same size as 100 mM CaCl2. 
Because barium has such a high affinity for alginate, less was needed for gel fabrication [2]. 
As hypothesized, DCs encapsulated in calcium-crosslinked alginate secreted significantly more 
IL-1β compared to DCs in barium-crosslinked gels (Figure 2.12A). LPS stimulation caused an overall 
increase in IL-1β, but the presence of calcium even further enhanced its secretion. Likewise, for both 
LPS-free and LPS conditions, DCs extracted from calcium-crosslinked alginate gels had increased 
expression of CD86 and MHC class II compared to DCs extracted from barium-crosslinked alginate gels 
(Figure 2.12B). 
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Figure 2.12 (Continued): Calcium crosslinker enhanced DC activation markers compared to barium crosslinker. 
(A) After 24 hours in culture, supernatants from DCs encapsulated in barium or calcium alginate beads, in the 
absence or presence of LPS, were collected and assayed for IL-1β. (B) DCs were extracted from beads and analyzed 
for CD86 and MHC class II using flow cytometry. Asterisks indicate that the calcium condition is significantly 
different from the barium condition. **P≤0.001. 
 
Since the calcium crosslinker was responsible for the enhanced IL-1β secretion and maturation 
marker expression observed with alginate gels, we hypothesized that DCs encapsulated in alginate gels 
with increasing concentrations of calcium crosslinker would have a dose-dependent response. Alginate 
droplets were crosslinked in a 10 or 100 mM CaCl2 bath as described above. Alginate beads crosslinked 
with 100 mM CaCl2 had slightly more precipitates than 10 mM CaCl2 gels (Figure 2.13A), which were 
formed during washing with PBS. Beads crosslinked with 100 mM CaCl2 raised the Ca2+ concentration of 
the medium up to 1.5 times higher than 10 mM gels (Figure 2.13B). Over time, the calcium released 
from both gel formulations began to precipitate in the medium, potentially accounting for the decrease 
in free Ca2+ seen at 4 and 10 hours. As expected, DCs in 100 mM gels stained more brightly with Fluo-4 
indicating that intracellular calcium concentration positively correlated with extracellular calcium 
concentration (Figure 2.13C). 
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Figure 2.13: Increasing CaCl2 crosslinker in alginate discs increased extracellular and intracellular Ca
2+. (A) 
Alginate beads (diameter≈2 mm) were crosslinked with 10 (left) or 100 mM (right) CaCl2. (B) Ca
2+ released into 
medium from 10 and 100 mM CaCl2 alginate gels was quantified over 10 hours. (C) DCs were labeled with Fluo-4, 
encapsulated in 10 or 100 mM CaCl2 alginate beads, and imaged with a fluorescent microscope to determine 
relative intracellular Ca2+ levels.  
 
DCs in CaCl2 gels appeared viable immediately after encapsulation but by 24 hours appeared 
necrotic (Figure 2.14A). Forward-side scatter analysis of DCs retrieved 24 hours after encapsulation 
confirmed that increasing CaCl2 crosslinker concentration by 10 fold decreased cell viability from 80% to 
50% and that LPS stimulation further decreased cell viability by 8 to 10 fold (Figure 2.14B).  
0
0.5
1
1.5
2
2.5
3
3.5
0 2 4 6 8 10 12
10 mM
100 mM
C
a2
+  
R
el
ea
se
 F
ro
m
 G
el
 (m
M
)
Time (Hours)
B
C
A 
 37 
 
 
                  
 
 
Figure 2.14: Increasing CaCl2 crosslinker decreased cell viability. (A) Photomicrographs were taken of DCs 
immediately after encapsulation (top) and 24 hours later (bottom). Images shown are the most representative. (B) 
DCs were extracted from beads and cell viability was quantified based on forward-/side-scatter measurements 
obtained using flow cytometry. 
 
Consistent with trends seen with calcium-supplemented R10, increasing the CaCl2 crosslinker 
from 10 mM to 100 mM induced secretion of all cytokines tested, particularly IL-1β, and enhanced LPS-
stimulated IL-1β secretion (Figure 2.15). Increasing CaCl2 also strongly enhanced the mean fluorescence 
intensity (MFI) of CD86lo for both LPS-free and LPS-stimulated cells (Figure 2.16A), enhanced the MFI of 
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MHC class IIlo for LPS-stimulated cells (Figure 2.16A), and significantly increased MHC class IIhiCD86hi 
double-positive expression (Figure 2.16B).  
 
Figure 2.15: Increasing CaCl2 crosslinker increased IL-1β secretion. After 24 hours in culture, supernatants from 
DCs encapsulated in alginate beads, in the absence or presence of LPS, were collected and multiplexed for 
cytokines. Asterisks indicate that the 100 mM condition is significantly different from the 10 mM condition. 
*P≤0.05; **P≤0.001.                   
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Figure 2.16: Increasing CaCl2 crosslinker upregulated DC activation markers. DCs were extracted from beads, 
stained with PE-labeled anti-CD86 and FITC-labeled anti-MHC class II, and analyzed using flow cytometry. (A) Live 
cells were gated into negative (neg), low (lo), or high (hi) populations. Filled gray histograms are isotype controls. 
(B) The percentage of MHC class IIhiCD86hi double-positive cells were calculated based on neg/lo/hi gating. 
Asterisks indicate that the 100 mM condition is significantly different from the 10 mM condition. **P≤0.001. 
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 To confirm that these results were not unique to CaCl2 crosslinked alginate gels and could 
extend to alginate gels crosslinked with other calcium crosslinkers, we tested alginate discs cured with 
10 or 40 mM CaSO4. Alginate gels cured with 40 mM CaSO4 crosslinker contained more calcium 
precipitates than 10 mM gels (Figure 2.17A) and increased the Ca2+ concentration of the surrounding 
medium to approximately 3 mM - about 2.5 times more than 10 mM gels (Figure 2.17B). For 40 mM gels 
the amount of calcium released over a 10 hour period equaled ~61% of the calcium initially incorporated 
into the gel, and for 10 mM gels the amount was ~34%. DCs in 40 mM gels stained more brightly with 
Fluo-4, indicating that intracellular calcium concentration positively correlated with extracellular calcium 
concentration (Figure 2.17C).  
 
 
 
 
                                               
 
Figure 2.17 
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Figure 2.17 (Continued): Increasing CaSO4 crosslinker in alginate discs increased extracellular and intracellular 
Ca2+. (A) Alginate discs (diameter=8 mm) were crosslinked with 10 (left) or 40 mM (right) CaSO4. (B) Ca
2+ released 
into medium from 10 and 40 mM CaSO4 alginate gels was quantified over 10 hours. (C) DCs were labeled with 
Fluo-4, encapsulated in 10 or 40 mM CaSO4 alginate discs, and imaged with a fluorescent microscope to determine 
intracellular Ca2+ levels. 
 
Like DCs in CaCl2 crosslinked gels, cells immediately after encapsulation appeared viable, but by 
24 hours they were noticeably unhealthy, with DCs in 40 mM gels appearing dark and granular (Figure 
2.18A). Forward-side scatter analysis of DCs retrieved 24 hours after encapsulation revealed that 
increasing CaSO4 crosslinker from 10 mM to 40 mM reduced the viability of encapsulated cells from 60% 
to 55% and that LPS stimulation further reduced cell viability by 2-3 fold (Figure 2.18B).  
 
 
                  
C 
 42 
 
 
 
 
Figure 2.18: Increasing CaSO4 crosslinker decreased cell viability. (A) Photomicrographs were taken of DCs 
immediately after encapsulation (top) and 24 hours later (bottom). Images shown are the most representative. (B) 
DCs were extracted from discs and cell viability was quantified based on forward-/side-scatter measurements 
obtained using flow cytometry. 
 
Consistent with results from CaCl2 crosslinked gels, supernatants collected and analyzed after 24 
hours showed that IL-1β secretion increased with increasing CaSO4 crosslinker (Figure 2.19). 
Additionally, increasing CaSO4 crosslinker from 10 mM to 40 mM noticeably enhanced the percentage of 
CD86hi cells for both LPS-free and LPS conditions (Figure 2.20A) as well as MHC class IIhiCD86hi double-
positive cells for the LPS condition (Figure 2.20B). 
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Figure 2.19: Increasing CaSO4 crosslinker increased IL-1β secretion. After 24 hours in culture, supernatants from 
DCs encapsulated in alginate discs, in the absence of LPS or with LPS stimulation, were collected and multiplexed 
for cytokines. Asterisks indicate that the 40 mM condition is significantly different from the 10 mM condition. 
*P≤0.05; **P≤0.001. 
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Figure 2.20 (Continued): Increasing CaSO4 crosslinker upregulated DC activation markers. DCs were extracted 
from discs, stained with PE-labeled anti-CD86 and FITC-labeled anti-MHC class II, and analyzed using flow 
cytometry. (A) Live cells were gated into negative (neg), low (lo), or high (hi) populations. Filled gray histograms are 
isotype controls. (B) The percentage of MHC class IIhiCD86hi double-positive cells were calculated based on 
neg/lo/hi gating. Asterisks indicate that the 40 mM condition is significantly different from the 10 mM condition. 
**P≤0.001. 
 
 To establish that DCs cultured externally from gels could also be matured by calcium alginate 
gels, DCs were plated on TCPS in the absence or presence of alginate gels crosslinked with barium or 
calcium. DCs cultured in the presence of calcium alginate gels secreted significantly higher 
concentrations of IL-1β (Figure 2.21A) and expressed higher levels of CD86 and MHC class II (Figure 
2.21B) compared to control and barium alginate conditions.  
 
  
Figure 2.21: Calcium crosslinker enhanced DC activation markers compared to barium crosslinker. (A) After 24 
hours in culture, supernatants from DCs plated on TCPS and cultured in the presence of barium or calcium alginate 
gels were collected and assayed for IL-1β. (B) DCs were scraped from wells and analyzed for CD86 and MHC class II 
using flow cytometry. **P≤0.001. 
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2.4 Discussion 
 
The results of this study indicate that the Ca2+ used to crosslink alginate gels was released over 
time and promoted IL-1β, CD86 and MHC class II expression by DCs, whether they were encapsulated 
within gels or cultured externally from gels in vitro. In addition to increasing DC maturation, increasing 
calcium crosslinker was also associated with increasing intracellular Ca2+ and reduced cell viability.  
Contrary to published data showing that alginate polysaccharides could stimulate inflammatory 
cytokine production from monocyte populations, the various soluble alginate polysaccharides used in 
these experiments did not stimulate DCs. Alginate has been suggested to activate monocytes and 
macrophages, potentially via the NF-κB pathway [10, 11, 15-17], and several studies have reported the 
detection of antibodies against alginate in vivo [18-20]. Conflicting with this, alginate has been used as 
an anti-inflammatory to suppress experimental glomerulonephritis and ulcerative colitis [12, 21]. The 
literature on alginate immunogenicity is abundant yet controversial, and many of these results must be 
interpreted with caution as alginates used in past studies may have contained impurities such as 
endotoxins, residual proteins, or polyphenols, all of which affect the immunogenicity of alginate [13, 22-
24]. The alginate used in this study was of ultrapure grade, which may explain why no 
immunostimulatory effects were seen. 
Although agarose polymers did not induce or affect DC activation, it was observed that whole 
agarose gels had a unique effect on DC activation. The gels themselves did not induce cytokine secretion 
from DCs but greatly enhanced TNF-α production when DCs were pulsed with LPS. It has been shown 
that heat shock proteins (HSPs) play an important role as molecular chaperones of the LPS-signaling 
pathway [25, 26], and it is possible that the heated agarose, although cooled near body temperature 
before use, elicited the production of HSPs by DCs, subsequently enhancing TNF-α secretion when the 
cells were exposed to LPS. Although further testing would have to be done to confirm this, it is an 
interesting idea that could be used advantageously to activate white blood cells. 
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Calcium alginate gels increased the concentration of calcium in the medium up to 5 mM (2.5 
times what is physiologically relevant) over a 10 hour period, and Fluo-4 labeling revealed that the 
elevated level of extracellular calcium, whether it be on TCPS or with alginate gels, resulted in a 
sustained increase in intracellular Ca2+. The exact mechanism(s) of increased cytosolic Ca2+ in this study 
was not determined, but it was likely due to a series of events leading to contributions from both 
extracellular Ca2+ and intracellular Ca2+ stores [27, 28]. Given the intricately intertwined activities of ion 
channels, pumps, transporters, intracellular buffers, Ca2+-binding proteins and organelles, all of which 
affect cytosolic Ca2+ [28], one would have to use more sophisticated techniques, such as patch clamp 
techniques, to precisely determine the mechanisms of increased intracellular Ca2+ in these experiments.  
A critical finding of this study was that increasing calcium matured DCs and enhanced LPS-
induced DC activation. As discussed in Chapter 1, dendritic cells are highly dependent on Ca2+ to carry 
out their effector functions, and several intracellular Ca2+-sensing and -signaling molecules have been 
identified as having necessary roles in DC activation and antigen presentation [29, 30]. It is likely that the 
increases in intracellular calcium induced by raising extracellular calcium activated these Ca2+ signaling 
molecules leading to the upregulation of activation marker expression and inflammatory cytokine 
secretion. These results illustrate how one can amplify gene expression by increasing a second 
messenger (in this case calcium) that is downstream of a signaling event (such as TLR signaling). It is also 
plausible that the calcium being released from the alginate gels was sensed externally by CaR, initiating 
various signaling pathways leading to expression of inflammatory markers. 
One of the most striking findings was the increase in IL-1β observed with calcium alginate gels. 
IL-1β is a critical mediator of inflammation, with important roles in neutrophil mobilization, cellular 
adhesion to the endothelium, and white blood cell infiltration [31, 32]. Cleavage of pro-IL-1β into its 
functional, secreted form is predominantly mediated by the NRLP3 inflammasome, an important 
molecular platform expressed by myeloid cells in innate immune defense that can be activated by a 
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number of danger signals and stress factors [33]. A connection has been made between Ca2+-induced 
mitochondrial damage and activation of the NLRP3 inflammasome, which likely explains the increase in 
IL-1β [33-35]. Inflammasome activation has been implicated in the success of adjuvants, such as alum 
[36, 37], which suggests that calcium alginate induction of IL-1β (and potentially inflammasome 
activation) may have interesting implications in the field of vaccination. 
The calcium levels in this study correlated with reduced cell viability in a dose-dependent 
manner. This is consistent with past reports showing that elevations in intracellular calcium can directly 
and indirectly induce cell injury and death [38]. The largest contributor to Ca2+ toxicity is believed to be 
Ca2+-induced mitochondrial permeability transition (MPT), which is the formation of a large pore in the 
mitochondrial membrane during mitochondrial stress [38]. When cytosolic Ca2+ is elevated (>500 nM), 
mitochondria can be destabilized, initiating MPT, and resulting in the release of pro-apoptotic proteins. 
Cell death due to Ca2+ toxicity may have accounted for decreases in IL-1β seen with TCPS for calcium 
concentrations above 3 mM. Additionally, LPS-induced TNF-α secretion could have triggered apoptosis 
via the TNF pathway and accounted for the decreased viability seen with LPS-treated conditions [39].  
Increasing calcium crosslinker increases alginate gel stiffness [3], which could potentially affect 
the behavior of encapsulated DCs as reported for other adherent cells [40]. However, since the alginate 
used in this study was not modified with integrin ligands, such as Arg-Gly-Asp (RGD) peptide, the DCs 
were not able to attach to the surrounding matrix, and it is questionable whether the DCs encapsulated 
within the gels could sense or be strongly affected by gel stiffness. Further studies are needed to 
confirm this. In contrast, the high stiffness of TCPS could account for the high levels of IL-6 secreted by 
DCs cultured on TCPS compared to the other materials. DCs on TCPS also appeared more elongated as 
calcium increased. It is unclear whether this was an indirect consequence of the calcium activating DCs 
(and subsequently the formation of dendrites), a direct consequence of the calcium affecting integrin 
binding, or other mechanisms. 
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In conclusion, the data collected in this study suggests that the calcium used to crosslink alginate 
gels matures DCs and opens the idea that other biomaterials, aside from alginate, may be useful in 
controlling calcium signaling to affect DC behavior.  
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Chapter 3 
Effect of Calcium Ionophore A23187 on Dendritic Cells In Vitro 
 
3.1 Introduction 
 The ionophore A23187 is a lipid-soluble mobile ion carrier (523.62 g/mol) that is commonly used 
to raise cytosolic calcium levels (Figure 3.1A) [1]. It binds to divalent cations in a 1:2 ratio with high 
affinity, in the order Mn2+>>Ca2+>Mg2+>>Sr2+>Ba2+ [2], and very weakly to monovalent ions making it 
capable of inducing Ca2+-dependent signaling pathways without perturbing the balance of Na+ and K+ [3]. 
A23187 and other calcium ionophores  are thought to increase cytosolic calcium by depleting 
intracellular stores of Ca2+ leading to the influx of extracellular calcium to replenish intracellular stores 
[4-8]. Studies show that in myeloid cells, A23187-induced elevations in cytosolic calcium are associated 
with the activation of calcineurin phosphatase and protein kinase C leading to the acquisition of 
morphologic, phenotypic, and functional traits of mature DCs [9, 10]. Because of its ability to induce 
mature DC characteristics, A23187 has been tested on monocytes and dendritic cells isolated from 
peripheral blood as a means to mature them ex vivo for dendritic cell-based immunotherapy [11, 12]. 
Additionally, it has been studied for its ability to differentiate myeloid leukemia cells into antigen 
presenting cells ex vivo for anti-leukemia therapy (for more information, see Appendix 2) [13-16]. 
 A23187 is a potent dendritic cell stimulator, but given the universality of calcium signaling, it is 
impractical to administer it systemically. We hypothesized that we could demonstrate A23187’s release 
from biomaterials in vitro, which could then be used to target A23187 to dendritic cells for potential use 
in immunotherapy in vivo. Our starting approach was modeled after PLG  scaffolds described in Chapter 
1 that contained GM-CSF to recruit DCs and danger signals and tumor lysates to program an anti-cancer 
response [17]. First, we verified the immunostimulatory effects of A23187 on bone marrow-derived 
dendritic cells in vitro and compared its effects to monensin, a lipid-soluble sodium ionophore. To gauge 
DC maturation we analyzed cytokine secretion, activation marker expression, and antigen cross-
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presentation. Second, we encapsulated A23187 (a hydrophobic molecule) in both PLG matrices (a 
hydrophobic material) and calcium alginate gels (a hydrophilic material) to determine if it could be 
released in vitro. Delivery from calcium alginate gels could be appealing given the high concentration of 
immunostimulatory calcium in the gels and the ability to inject it making it easier to introduce in the 
body. If successful, an implantable or injectable scaffold containing a chemoattractant and A23187 could 
be used to recruit local DCs and enhance their activation in situ. 
 
Figure 3.1: Structure of A23187. A23187 (523.62 g/mol) binds to divalent cations, such as Ca2+, with high affinity. 
Two A23187 molecules bind to every one Ca2+ ion.  
 
3.2 Materials and Methods 
Cell Culture 
Bone marrow-derived DCs were cultured according to methods described in Chapter 2 and used 
for all experiments. 
 
Cell Viability 
 DCs were harvested, washed, and resuspended in R10 at a concentration of 555,556 cells/ml, 
and 1.8 ml (106 cells) were plated in 6-well plates. After 1 hour of incubation, 200 µl of control R10 or 
R10 containing A23187 (Sigma-Aldrich) was added so that the final concentration equaled 400, 800, 
1600, or 2000 ng/ml A23187. After 20-24 hours of activation, cells were scraped from wells and cell 
viability was quantified based on forward-/side-scatter measurements obtained using flow cytometry. 
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Intracellular Calcium Assay 
To measure intracellular calcium, cells were labeled with the fluorescent intracellular calcium 
probe Fluo-4 AM. DCs were harvested, washed in PBS, and resuspended at a density of 106 cells/ml in 5 
µM Fluo-4 AM in PBS for 30 minutes at room temperature. Labeled cells were then washed in PBS and 
allowed to sit for another 30 minutes to allow for complete de-esterification of the probe. Cells were 
spun and resuspended at a density of 888,889 cells/ml in control R10 or R10 containing 400 ng/ml 
A23187, and 180 µl (160,000 cells) were plated into 96-well plates. Immediately, fluorescence was 
measured using a Synergy™ HT microplate reader (Ex. 488 nm, Em. 516) at multiple timepoints after 
plating. For all intracellular calcium studies, the anti-FITC antibody A889 was diluted in the medium 
1:200 to quench background fluorescence. 
 
Cell-Surface Marker Analysis 
Cells were harvested, washed, and resuspended in R10 at a density of 666,667 cells/ml, and 1.5 
ml (106 cells) were plated in 6-well plates. After an hour of adherence, 500 µl of control R10 or R10 
containing A23187, CpG (InvivoGen, San Diego, CA), or both, were added to the wells for a final 
concentration of 400 ng/ml A23187 and/or 1 µM CpG. After 20-24 hours of activation, cells were 
scraped from wells and stained with APC-conjugated anti-mouse CD11c, FITC-conjugated anti-mouse 
MHC class II, PE-conjugated anti-mouse CD86, and PE-Cy7-conjuated anti-mouse CCR7 (eBioscience). 
Cell-surface antigen staining was analyzed using an LSR II or LSR Fortessa™ flow cytometer. Cell viability 
was determined using SSC vs. FSC, and only viable cells were gated for surface marker analysis. 
Supernatants were frozen at -20°C for cytokine analysis. 
For monensin studies, DCs were resuspended in R10 at a density of 555,556 cells/ml, and 1.8 ml 
(106 cells) were plated in 6-well plates. After one hour of adherence, 200 µl of control R10 or R10 
containing A23187 or monensin sodium salt (Sigma-Aldrich) was added so that the final concentration 
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equaled 400 ng/ml A23187 (0.76 µM) or 526.6 ng/ml monensin (0.76 µM).  After 20-24 hours, cells were 
collected, stained, and analyzed as above. Supernatants were frozen at -20°C for cytokine analysis. 
 
Cytokine Analysis 
Cell culture supernatants were analyzed with the Bio-Plex Pro™ Mouse Cytokine 23-plex Assay 
System or IL-1β and TNF-α Quantikine Colorimetric Sandwich ELISA kits (R&D Systems, Minneapolis, 
MN).  
 
Microscopy 
Cells were imaged with an EVOS fl microscope 20-24 hours after plating. 
 
Cross Presentation Studies 
 To determine if A23187 could enhance cross presentation, DCs were harvested, washed, and 
resuspended in R10 at a concentration of 555,556 cells/ml. 1.8 ml (106 cells) were plated in 6-well 
plates. After 1 hour of incubation, 200 µl of control R10 or R10 containing A23187, ovalbumin (Sigma-
Aldrich), OVA257-264 (SIINFEKL) (21st Century Biochemicals, Marlboro, MA), ovalbumin+A23187, or 
SIINFEKL+A23187  were added to wells for a final concentration of 400 ng/ml A23187, 10 µM ovalbumin, 
and/or 10 µM SIINFEKL. After 20 hours, DCs were scraped from wells, stained with PE-conjugated anti-
mouse OVA257-264 peptide bound to H2Kb (eBioscience) and analyzed using flow cytometry.  
To determine if maturation by A23187 prior to addition of antigen would downregulate cross 
presentation, DCs were harvested, washed, and resuspended in R10 at a concentration of 555,556 
cells/ml. 1.8 ml (106 cells) were plated in 6-well plates. After 1 hour of incubation, 200 µl of control R10 
or R10 containing A23187, SIINFEKL, or both were added to wells for a final concentration of 400 ng/ml 
A23187 and/or 10 µM SIINFEKL. After another 2 hours of incubation, 20 µl of 1 mg/ml SIINFEKL in water 
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was added to control wells or wells treated with A23187 so that the final concentration equaled 10 µM. 
20 µl of water was added to the remaining wells. After 22 hours, cells were scraped from wells, stained, 
and analyzed as above. This procedure was repeated for 7 and 20 hours. 
 To determine if A23187 treatment could affect cross presentation after the addition of SIINFEKL, 
similar experiments as above were repeated, except at 2, 7 and 20 hours, 0.8 µl of 1 mg/ml A23187 in 
DMSO was added to wells treated with SIINFEKL so that the final concentration equaled 400 ng/ml. 0.8 
µl of DMSO was added to the remaining wells. 
 
Delivery of A23187 from PLG Scaffolds 
 85:15 PLG (DLG 7E; Lakeshore Biomaterials, Birmingham, AL) microspheres encapsulating 
A23187 were fabricated by dissolving A23187 in a PLG/ethyl acetate solution and using an oil-in-water 
emulsion method as previously described [17, 18]. Lyophilized microspheres were then mixed and 
compressed with sucrose porogen and leached into macroporous scaffolds; ethanol sterilization was 
skipped [17, 18]. The amount of A23187 added to the PLG/oil phase during microsphere fabrication was 
such that the final amount in each 18 mg scaffold (8.5 mm diameter) equaled 180 µg A23187 assuming 
100% encapsulation efficiency. To measure release, leached scaffolds were placed in 15 ml 
polypropylene tubes containing 1 ml PBS and placed on an orbital shaker at 37°C. On days 1, 2, 3, 5, 9, 
13, and 25, the PBS was collected and frozen, and 1 ml of fresh PBS was added back to the tube. At the 
end of the study, scaffolds and PLG microspheres used to make the scaffolds were dissolved in ethyl 
acetate, and an A23187 standard curve (1, 0.5, 0.1, 0.05, 0.01, 0.005, and 0.001 mg/ml) was made in 
ethanol. The amount of A23187 in the dissolved microspheres, dissolved scaffolds, sucrose leach, and 
PBS release solutions were quantified using liquid chromatography-mass spectrometry (LC-MS) (Agilent 
1290 Infinity LC/6140 Quadrupole MSD) (Agilent Technologies, Santa Clara, CA). A Zorbax Eclipse Plus 
C18 Rapid Resolution HD column (1.8 µm, 2.1 mm x 50 mm i.d.) (Agilent Technologies) was used with a 
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gradient of 5% solvent B  (0.1% formic acid in acetonitrile) to 100% solvent B over 10 minutes at a flow 
rate of 1 ml/min. Solvent A was 0.1% formic acid in water. 
 
Delivery of A23187 from Alginate Gels 
 DCs were harvested, washed, and resuspended in R10 at a concentration of 106 cells/ml, and 1 
ml (106 cells) was plated in 12-well plates. ThinCert™ cell culture transwells (translucent, 8 µm pore) 
(Grenier Bio-One) were placed on top of wells. After 1 hour of incubation, barium alginate gels (with or 
without A23187) or calcium alginate gels (with or without A23187) were added to the inserts so that the 
total concentration of A23187 in the wells equaled 400 ng/ml. To fabricate gels, a 2.5% Ultrapure MVG 
alginate solution in PBS containing 5 µg/ml A23187 was made by adding 5 µl of a 1 mg/ml A23187 
solution in DMSO to every 1 ml PBS and reconstituting a known mass of lyophilized alginate with the 
appropriate volume. The alginate solution was mixed with a 20 mM BaCl2 or 244 mM CaSO4 crosslinker 
solution in water using two syringes connected by a coupler in a 4:1 volume ratio so that the final gel 
contained 2% alginate and 4 mM barium or 48.8 mM calcium. 200 µl of gel was ejected into the 
ThinCerts and allowed to cure for 10 minutes, after which 600 µl of R10 was pipetted on top. For control 
wells, 600 µl of R10 was added directly to wells followed by 200 µl of control R10 or R10 containing 
A23187 for a final concentration of 400 ng/ml A23187. After 20-24 hours of culture on an orbital shaker, 
ThinCerts were removed, supernatants were collected and frozen at -20°C, and 1 ml of 50 mM EDTA was 
added to each well to aid in cell detachment. Cells were incubated at 37°C for 10 minutes and then 
scraped, washed, and stained with APC-conjugated anti-mouse CD11c, FITC-conjugated anti-mouse MHC 
class II, and PE-conjugated anti-mouse CD86 for flow cytometry analysis. 
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Graphs and Statistical Analysis 
Flow cytometry data was analyzed and plotted using FlowJo software, and all other graphs 
were made using Kaleidagraph software. Statistical analysis was performed using Microsoft Excel or 
Kaleidagraph software. A two-tailed Student’s t-test assuming equal variances was used when 
comparing two groups, and an ANOVA followed by a post-hoc Tukey test was used when comparing 
multiple groups. For all experiments n=3-4. Data is reported as the mean ± standard deviation. 
 
3.3 Results 
Effect of A23187 on DC Maturation In Vitro 
To analyze the effects of A23187, DCs were cultured in control medium or medium containing 
400 ng/ml A23187 (0.76 µM; a concentration typically used in vitro). Cells exposed to A23187 extended 
long dendritic cell processes, which is a characteristic of activated DCs (Figure 3.2). Their appearance 
was similar to cells cultured in medium containing 12 mM calcium, which was shown in Chapter 2. As 
the concentration of the ionophore increased above 400 ng/ml, a significant decrease in viability was 
observed (Figure 3.3). Thus, 400 ng/ml A23187 was used for all experiments. 
 
Figure 3.2: A23187 induced an activated DC morphology. Immature DCs were cultured in control medium or 
medium containing 400 ng/ml A23187. Photomicrographs were taken after 24 hours. 
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Figure 3.3: 400 ng/ml A23187 did not reduce cell viability. DCs were cultured in increasing concentrations of 
A23187. After 24 hours, cell viability was determined using FSC/SSC measurements obtained with flow cytometry. 
Asterisks indicate that the condition is significantly different from the control condition. *P≤0.05; **P≤0.001. 
 
 
Fluo-4 staining revealed that treatment with A23187 elevated intracellular calcium for the first 
hour before it returned to baseline (Figure 3.4). This is in contrast to high calcium-containing medium, 
which caused DCs to maintain high intracellular calcium levels over several hours. 
 
 
 
Figure 3.4: A23187 increased intracellular calcium for the first hour. DCs were labeled with Fluo-4 and cultured in 
control medium or medium containing 400 ng/ml of A23187. Fluorescence was measured at various timepoints 
using a plate reader. 
 
 
Supernatants were next multiplexed for 22 pro-inflammatory cytokines and chemokines as well 
as IL-10, which is often considered a regulatory cytokine. We found that A23187 alone upregulated a 
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number of inflammatory mediators (Figure 3.5A and B), but even more striking was that A23187 was 
able to significantly enhance CpG-induced cytokine secretion (Figure 3.5A and C). One interesting 
observation was that chemokines such as MIP-1β (CCL4), RANTES (CCL5), MIP-1α (CCL3), KC (CXCL1) and 
MCP-1 (CCL2), which are all chemokines secreted by a number of immune cells, such as monocytes, 
macrophages, dendritic cells and neutrophils, to enhance granulocyte infiltration, tended to be secreted 
in higher concentrations with stimulation (Figure 3.5A). In terms of fold upregulation, A23187 alone 
upregulated IL-4 (a TH2 cytokine) the most, by ~40 fold (Figure 3.5B). A23187 alone also induced large 
fold increases in TNF-α, MIP-1α, IL-1α, and IL-6 (Figure 3.5B). Interestingly, when DCs were treated with 
CpG, not only was overall cytokine secretion significantly higher, but a different profile of inflammatory 
cytokines was upregulated (Figure 3.5C). With CpG alone, the greatest fold increase was observed with 
IL-6 (~1500 fold increase) followed by IL-12p40 (~500 fold increase) (Figure 3.5C); when A23187 was 
present, the effect of CpG activation was more than tripled (Figure 3.5C).  
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Figure 3.5 (Continued): A23187 promoted inflammatory cytokine secretion. DCs were cultured in control R10 or 
R10 containing A23187, CpG, or both. After 24 hours, supernatants were collected and multiplexed for cytokines. 
(A) The absolute amounts of cytokines and chemokines secreted by DCs were determined. (B) The fold increase in 
cytokine secretion that A23187 induced over control cells was calculated. (C) The fold increases in cytokine 
secretion induced by CpG and A23187+CpG over control cells were calculated. 
 
 
The expression of cell surface activation markers followed a similar trend as cytokine secretion. 
CpG induced greater MHC class II, CD86, and CCR7 expression than A23187 alone, but the combination 
of CpG and A23187 had the strongest effect (with the exception of MHC class II, which decreased) 
(Figure 3.6). The presence of A23187 during CpG activation was able to increase CD86 expression from 
~57% to ~87% and increase CCR7 expression from ~46% to ~82%. 
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Figure 3.6: A23187 promoted expression of cell surface activation markers. DCs were cultured in control R10 or 
R10 containing A23187, CpG, or both. After 24 hours, cells were collected and stained with fluorescently-tagged 
antibodies specific for MHC class II, CD86, and CCR7. Cells were analyzed by flow cytometry and gated into 
negative, low, and high (hi) populations for quantification. Asterisks indicate that the condition is significantly 
different from the control condition. **P≤0.001. 
  
To verify that A23187 was upregulating inflammatory markers by specifically enhancing calcium 
signaling, monensin sodium salt, a lipid-soluble ionophore that binds strongly to Na+ and is commonly 
used to block intracellular transport (and thus, having the opposite effect of A23187) [19], was tested as 
a negative control (Figure 3.7A). As expected, A23187 enhanced IL-1β, TNF-α, MHC class II, and CD86 
compared to control cells, whereas monensin downregulated these markers (Figure 3.7B and C). This 
data indicated that maturation of DCs by A23187 was specifically due to calcium modulation and not 
because of a non-specific effect of lipid-soluble ionophores.  
 
 
Figure 3.7 
0
20
40
60
80
100
MHCIIhi CD86hi CCR7hi
Con
A23187
CpG
CpG+A23187
%
 P
os
iti
ve
A
**
**
**
**
**
**
**
**
**
 62 
 
 
 
Figure 3.7 (Continued): A23187 had the opposite effect of monensin, a lipid-soluble sodium ionophore. (A) 
Monensin sodium salt (692.85 g/mol) binds to monovalent cations, such as Na+, with high affinity. (B) Cells were 
cultured in control R10 or R10 containing 0.76 µM monensin or 0.76 µM A23187. After 24 hours, supernatants 
were collected and analyzed for IL-1β and TNF-α by ELISA. (C) Cells were also collected and stained for MHC class II 
and CD86. Cells were analyzed by flow cytometry and gated into negative, low, and high (hi) populations for 
quantification. **P≤0.001. 
  
The effect of A23187 on cross-presentation was next examined by culturing DCs with ovalbumin 
(OVA) or SIINFEKL, a peptide derived from ovalbumin, with or without A23187. The presence of A23187 
was able to increase the brightness of MHCI-SIINFEKL staining by more than 2-fold for cells exposed to 
SIINFEKL and almost 3-fold for cells exposed to ovalbumin (Figure 3.8). Because DCs exposed to SIINFEKL 
had overall brighter staining than cells exposed to OVA, it was used for subsequent experiments. 
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Figure 3.8: A23187 enhanced cross-presentation. DCs were cultured with SIINFEKL or OVA with or without 
A23187. After 20 hours, cells were collected, stained with anti-SIINFEKL bound to MHC class I, and analyzed by flow 
cytometry. **P≤0.001. 
  
When co-delivering multiple factors from biomaterials, it is important to determine the optimal 
sequence of drug delivery. It has been demonstrated that when DCs mature, their ability to uptake, 
process, and present antigen is downregulated [20]. Thus, it was important to determine if pretreatment 
of DCs with A23187 inhibited cross presentation, as this would impact the design of a material that 
could co-deliver A23187 with antigens and other signals. To test this in vitro, DCs were pre-treated with 
A23187 for 2, 7, or 20 hours and then exposed to SIINFEKL for an additional 22 hours. Staining for 
SIINFEKL bound to MHC class I revealed that pretreatment of DCs with ionophore did not downregulate 
cross presentation. In fact, for all pretreatment times, A23187 continued to strongly upregulate cross 
presentation (Figure 3.9A). When DCs were exposed to SIINFEKL for 2, 7, or 20 hours prior to 22 hours of 
A23187 treatment, A23187 continued to enhance cross presentation (Figure 3.9B). However, for the 20 
hour condition, DCs had an overall reduced expression of MHCI-SIINFEKL, which was potentially due to 
degradation of the peptide. 
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Figure 3.9: A23187 enhanced cross presentation whether it was administered to DCs before or after SIINFEKL 
addition. (A) DCs were pretreated with A23187 for 2, 7, or 20 hours before SIINFEKL addition. 22 hours after 
SIINFEKL addition, cells were stained with anti-SIINFEKL bound to MHC class I and analyzed by flow cytometry. (B) 
DCs were exposed to SIINFEKL 2, 7, or 20 hours prior to A23187 treatment. 22 hours after A23187 treatment, cells 
were stained and analyzed as above. For control conditions, DCs were treated simultaneously with A23187 and 
SIINFEKL. Filled gray histograms are isotype controls. 
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Delivery of A23187 from PLG and Alginate Scaffolds 
As a starting point, we tested whether A23187 could be released from PLG scaffolds that were 
previously developed for immunotherapy [17, 18]. LC-MS was used to quantify the release of A23187 
from these scaffolds. Using the protocol described in 2.2 Materials and Methods, A23187 was found to 
elute at approximately 7.38 minutes and have a mass of 522.2 g/mol (Figure 3.10A and B). The lower 
limit of detection was ~0.001 mg/ml.  
 
 
                                                       
                                             
 
Figure 3.10: A23187 was detected by LC-MS. (A) Chromatogram of 1 mg/ml A23187. A23187 eluted at ~7.38 
minutes. (B) Mass spectrum of A23187.
 
Encapsulation efficiency was determined to be ~65-89%; of the original 180 µg of A23187 used 
for scaffold fabrication, only 118-160 µg was actually encapsulated within scaffolds. A23187 was not 
detected in the porogen leach or throughout the release study (Figure 3.11). At the end of the study, the 
A
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total amount of A23187 initially incorporated still remained in the scaffolds, demonstrating that 
although A23187 had a high encapsulation efficiency in PLG scaffolds, it was released poorly into PBS.
 
Figure 3.11: A23187 released poorly into PBS from PLG scaffolds. A23187 was encapsulated in PLG scaffolds, 
which were placed at 37°C on a rocker in 1 ml PBS. PBS was collected and replaced at various timepoints over 24 
days. At the end of the study, collected samples were tested for A23187 using LC-MS. 
  
We next tested whether A23187 could be delivered from calcium alginate hydrogels to activate 
DCs in vitro. Because the amount of ionophore encapsulated in gels fell below the LC-MS level of 
detection, functional assays were used to determine its release. In these studies, the total amount of 
A23187 added to each well for the ionophore conditions was identical, whether it was added directly to 
the medium or via alginate hydrogels. Interestingly, in contrast to previous studies, calcium alginate gels 
alone (Ca) did not stimulate detectable IL-1β, but A23187 delivered from calcium alginate gels 
(Ca+A23187) in the first 24 hours more than tripled IL-1β secretion compared to A23187 delivered from 
barium alginate gels (Ba+A23187) and A23187 pipetted directly into the medium (A23187) (Figure 
3.12A). Calcium alginate gels alone elevated CD86 expression (~53%) compared to barium alginate gels 
alone (Ba) (~49%) and the control condition (Con) (~48%), whereas all conditions containing A23187 
increased CD86 expression to ~90% or higher (Figure 3.12B). Given that the A23187 released from 
alginate gels induced a similar or more enhanced degree of DC maturation compared to A23187 added 
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directly to wells, it is likely that all of the A23187 encapsulated in gels was released over the first 24 
hours.  
 
 
Figure 3.12: A23187 was released from barium and calcium alginate matrices. DCs were cultured in 12-well 
plates, and barium or calcium alginate gels with or without A23187 were cured in transwells placed above the 
cells. As a positive control, A23187 was added directly to wells. (A) Cells were cultured for 24 hours on an orbital 
shaker and supernatants were collected and analyzed for IL-1β. (B) Cells were also collected and stained with anti-
CD86 and analyzed by flow cytometry. 
 
3.4 Discussion 
 The results of this study confirm that A23187, a lipid-soluble calcium ionophore, is a potent 
activator of DCs, upregulating pro-inflammatory cytokines, cell surface activation markers, and antigen 
cross-presentation. The ionophore had a high encapsulation efficiency in PLG microspheres, but due to 
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its high affinity for the polymer, released very poorly into PBS. In contrast, A23187 released readily from 
barium and calcium alginate matrices. 
 Maturation of DCs by calcium ionophores is associated with the activation of NF-κB and the 
CaMKII pathway, which promote Signal 1 (antigen presentation on MHC molecules), Signal 2 (co-
stimulatory molecules such as CD86), and Signal 3 (cytokine secretion) [20-22]. In our studies, A23187 
promoted DC maturation, which was indicated by DC morphology, cytokine secretion, co-stimulatory 
molecule expression, and cross-presentation. Additionally, we observed that CCR7, a chemokine 
receptor that allows DCs to home to lymph nodes and prime T-cell responses, was also upregulated 
upon A23187 treatment – another sign of DC maturation [23]. These changes were accompanied by 
increases in cytosolic calcium. Although A23187 alone did not induce DC maturation as strongly as CpG, 
A23187 dramatically increased CpG-induced cytokine secretion by several orders of magnitude and 
enhanced CpG-induced CD86 and CCR7 expression. This suggests that calcium ionophores could be 
extremely useful in boosting the effects of adjuvants for vaccination.  
Interestingly, when DCs were treated with ionophore only, a different profile of inflammatory 
cytokines was upregulated when compared to CpG only. IL-4, a TH2 cytokine, dominated the response to 
A23187 alone, possibly suggesting that DC maturation in the absence of TLR signaling can skew DCs 
towards a TH2 phenotype. Additionally, A23187 induced a different cytokine profile compared to 
calcium alginate gels. For instance, IL-6 and TNF-α were more strongly upregulated by A23187, whereas 
IL-1β was more strongly upregulated by calcium alginate gels. This could potentially be due to 
differences in inflammasome activation, which demonstrates that although A23187 and calcium 
crosslinker activate many overlapping signaling pathways, their effects are not completely identical. 
These results could have an important impact on our understanding of DC biology. 
Dendritic cells are highly sensitive to external stimuli and we wanted to verify that the 
immunostimulatory effects induced by A23187 were not a non-specific effect of lipid-soluble 
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ionophores. Thus, monensin, a lipid-soluble ionophore that binds to monovalent cations, was also tested 
for its ability to stimulate dendritic cells. Monensin binds strongly to Na+ ions and is capable of 
disrupting the Na+/H+ exchange across the Golgi apparatus. This occurs when increases in intracellular 
Na+ induced by monensin cause an efflux of H+ from the Golgi, leading to neutralization of acidic Golgi 
compartments and a reduction in protein transport to the cell surface [19]. Because of this effect, 
monensin is a common experimental tool used to block intracellular transport for intracellular cytokine 
staining. We hypothesized that if the ionophores were acting specifically on DCs and altering ion 
signaling, A23187 and monensin would have opposite effects. As hypothesized, monensin reduced the 
expression of inflammatory markers, while A23187 enhanced them compared to control cells. Not only 
do these results validate that monensin and A23187 are specifically altering intracellular Na+ and Ca2+, 
respectively, but they also make it evident that other ions, such as sodium, can be targeted in vivo to 
control other aspects of cell behavior. 
Past studies have shown that maturation causes DCs to reduce their antigen uptake and 
processing capabilities, so it was important to determine if A23187 would have this effect, as this would 
affect drug delivery design. Surprisingly, we did not observe a reduction in antigen presentation in 
studies where DCs were pre-treated with A23187 prior to antigen exposure. This could potentially be 
due to the fact that the DCs in these particular studies were not exposed to traditional danger signals, 
which may have an important role in dictating phagocytosis and antigen presentation signaling 
pathways. To test this, the experiments could be repeated but include a positive control such as LPS or 
CpG. 
 A23187 had a high encapsulation efficiency (65-89%) in PLG scaffolds and released poorly into 
PBS. This is not surprising given the hydrophobicity of ionophores. It is possible that if release studies 
were performed in complete medium containing carrier proteins, A23187 would release more readily 
from scaffolds. However, these studies were not performed because it would have been difficult to use 
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LC-MS to detect A23187 in the presence of serum proteins. Future studies could involve in vitro 
functional assays where DCs were seeded directly onto scaffolds or at the bottom of wells with scaffolds 
placed in transwells above. Experiments in complete medium such as these would better recapitulate 
the in vivo environment than PBS. Another option would be to implant scaffolds directly in vivo, remove 
them periodically, and analyze them for remaining A23187 using more sophisticated analyses. If A23187 
release kinetics were still poor, the properties of the PLG could be tuned to accelerate the release of 
ionophore from the scaffolds.  
 Given the high concentration of calcium in calcium alginate gels, the strong interactions 
between calcium and A23187, and the hydrophilic nature of the material, we were interested in seeing if 
A23187 could be encapsulated and released from calcium alginate matrices. Delivery from calcium 
alginate matrices is attractive, not only because it provides an immunostimulatory calcium source, but 
because it can be injected minimally-invasively making it easier to administer. Here, we did not have to 
worry about the ionophore significantly chelating the calcium crosslinker, since the concentration of 
A23187 incorporated in gels (7.6 µM) was approximately 4 orders of magnitude lower than the calcium 
crosslinker concentration (48.8 mM). However, we considered that the high concentration of calcium in 
the gel could sequester the ionophore and prevent it from leaving the gel; our results indicated that this 
was not the case. The A23187 released from barium gels induced a similar magnitude of IL-1β secretion 
as cells exposed to A23187 added directly to the medium, suggesting that all of the A23187 was 
released from gels within the first day. Moreover, A23187 released from calcium-crosslinked gels 
induced significantly more IL-1β secretion compared to all other conditions, demonstrating that A23187 
and calcium released from the gels had an additive impact. These results demonstrated that in contrast 
to PLG scaffolds, A23187 was released quickly from calcium alginate gels and had a strong effect on DC 
activation in vitro. 
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Unlike earlier studies (see Chapter 2), IL-1β could not be detected from DCs exposed to calcium 
alginate gels only. This is possibly due to gels being in a separate compartment during culture leading to 
altered calcium diffusion and a weaker impact on DC maturation. In earlier studies, cells were also 
cultured on a larger surface area and alginate gels were in direct contact with cells, which could account 
for the differences in IL-1β and CD86 seen between the different experiments. Lastly, control cells in 
past experiments secreted detectable levels of IL-1β, whereas control DCs in this experiment did not, 
suggesting that cells used in these experiments inherently produced less IL-1β. 
This chapter illustrates both the potent effect of ionophores on dendritic cell behavior and 
A23187’s ability to be incorporated into both hydrophobic (PLG) and hydrophilic (alginate) materials. 
More work will have to be done to better characterize ionophore release from these materials and to 
optimize them, or other potential materials, for ionophore delivery in vivo. For example, delivering too 
much ionophore could lead to destabilization of cell membranes of target cells and toxicity. In contrast, 
if cleared too quickly after released, the ionophore may have minimal, transient, or off-target effects. If 
calcium ionophores can be successfully delivered from biomaterials to have a strong, but safe impact on 
cells and tissues, this could be a powerful tool to manipulate cell behavior in vivo. 
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Chapter 4 
Enhancing Calcium Signaling In Vivo to Boost Local Inflammation 
 
4.1 Introduction 
Prior to the development of biomaterials for controlled drug delivery, the idea of harnessing 
calcium signaling in vivo to induce a potent and long-lasting immune response seemed impossible due to 
the universal role that calcium plays in the body and the detrimental side effects it could have on other 
cells and tissues. However, with the existence of biomaterials to target drugs to specific cells and 
locations in the body and their ability to sustain drug release, the idea of delivering calcium or calcium 
ionophores to white blood cells in vivo to enhance the immune response is now conceivable.  
The effects of calcium release and A23187 in vivo have not been well-studied, and given the 
body’s ability to buffer calcium and metabolize drugs, it is difficult to predict whether calcium or A23187 
could have a potent effect on white blood cells in the body. Because the use of A23187 in vivo is rare, 
the pharmacokinetics and pharmacodynamics of the molecule are largely unknown. However, A23187 
has been injected subcutaneously in vivo as a means to locally recruit lymphocytes [1, 2], which 
indicates that it can have a measurable inflammatory effect on surrounding tissue.  
Contrary to A23187, calcium alginate gels encapsulating growth factors, cells, and/or cytokines 
have been used in vivo for a wide variety of applications such as type I diabetes treatment [3], 
angiogenesis [4] and cancer immunotherapy [5, 6]. Nevertheless, none of these studies specifically 
examined the potential contribution of calcium to the final outcome. Interestingly, in a study where 
calcium-crosslinked alginate gels were used to deliver pro-angiogenic factors to enhance blood vessel 
formation [4], and in another study where they were used to deliver activated DCs peritumorally to 
reduce tumor growth [6], alginate gels alone appeared to have a slight therapeutic effect, but further 
work would have to be done to determine the cause. Although minimal, the evidence suggests that the 
calcium crosslinker released from alginate gels can have a local stimulatory effect. 
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Consequently, because calcium and A23187 released from alginate gels had such potent effects 
on DCs in vitro and because of evidence that calcium alginate and A23187 could have observable effects 
in vivo, we were interested in determining whether barium and calcium alginate gels, with or without 
A23187, injected subcutaneously into C576BL/6J mice could stimulate white blood cells. We 
hypothesized that the calcium used to crosslink alginate gels and/or delivery of A23187 could increase 
local inflammation in vivo. To test this, we examined the effects of the injection site, days of 
implantation, calcium crosslinker concentration, gel volume, and LPS delivery on inflammatory cytokine 
secretion from surrounding tissue.  
 
4.2 Materials and Methods 
Subcutaneous Alginate Injections 
Female C57BL/6J mice, ages 4-12 weeks, were anesthetized with isoflurane, and their backs 
were shaved and wiped with ethanol. A 2.5% MVG alginate solution in PBS was mixed with a sterile 20 
mM BaCl2 or 244 mM CaSO4 solution in water using two 1 ml syringes connected by a coupler. The 
volumes were mixed in a 4:1 ratio so that the final gel contained 2% alginate and 4 mM BaCl2 or 48.8 
mM CaSO4. For studies examining the effect of A23187, alginate gels encapsulating ionophore were 
fabricated according to methods described in Chapter 3 to yield 50 µl gels containing 0.4, 0.5, 0.6 or 0.8 
µg of ionophore; for studies examining the effect of calcium crosslinker concentration, 375 and 500 mM 
CaSO4 slurries were used to fabricate gels containing 75 and 100 mM calcium, respectively; and for 
alginate gels delivering LPS, MVG alginate was dissolved with PBS containing LPS so that final crosslinked 
gels contained 1 µg of LPS/50 µl gel. All gels were prepared aseptically. After mixing the dissolved 
alginate with the crosslinker, 50 or 100 µl of gel was injected subcutaneously with a 23 gauge needle in 
the left or right sides (lateral injection) or in the center of the back (medial injection) as indicated. Mice 
were allowed to recover and consume food and water ad libitum. At the timepoints specified, mice were 
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sacrificed and gels were removed with scissors and tweezers. Samples were frozen at -20°C until 
analysis. 
 
Cytokine Analysis 
Gels were digested with 100 µl of 10 unit/ml alginate lyase (Sigma) in a 37°C dry bath with 
occasional vortexing until fully dissolved. Digested alginate was analyzed with the Bio-Plex Pro™ Mouse 
Cytokine 23-plex Assay System or IL-1β and TNF-α Quantikine Colorimetric Sandwich ELISA kits. 
 
Calcium Release Assay 
Gels were digested as described above, diluted 1:4 in PBS, and assayed using the QuantiChrom™ 
Calcium Assay Kit. 
 
Graphs and Statistical Analysis 
Graphs were made using Kaleidagraph software. Statistical analysis was performed using 
Microsoft Excel or Kaleidagraph software. A two-tailed Student’s t-test assuming equal variances 
was used when comparing two groups, and an ANOVA followed by a post-hoc Tukey test was used when 
comparing multiple groups. For all experiments n=3-4 unless otherwise noted. Data is reported as the 
mean ± standard deviation. 
 
4.3 Results 
 To determine if the calcium in calcium alginate gels had an inflammatory effect in vivo, 50 µl 
barium (4 mM) and calcium (48.8 mM) alginate gels were injected subcutaneously into the lateral sides 
of mice. After 2 and 4 days, gels were removed and analyzed for IL-1β. For both timepoints, IL-1β was 
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undetectable for barium gels but detectable for calcium alginate gels, and there were no noticeable 
differences between days 2 and 4 (Figure 4.1).  
 
Figure 4.1: Calcium alginate gels enhanced IL-1β secretion in vivo. 50 µl barium or calcium alginate gels were 
injected subcutaneously into the lateral sides of mice. At days 2 and 4, gels were removed and analyzed for IL-1β. 
 
In Chapter 3 it was demonstrated that A23187 encapsulated in alginate gels could be released to 
mature DCs in vitro. Furthermore, it was demonstrated that A23187 could enhance IL-1β secretion 
induced by calcium alginate. To determine whether this could be repeated in vivo, 50 µl calcium alginate 
gels encapsulating 0.4, 0.5, 0.6, or 0.8 µg of A23187 (which fall within the range of what has been 
previously used to recruit lymphocytes) were injected into the lateral sides of mice and after 2 days 
were removed and analyzed for IL-1β and TNF-α. Unlike its effects in vitro, A23187 delivered from 
calcium alginate matrices in vivo did not induce more inflammatory cytokine secretion compared to gels 
without A23187 (Figure 4.2). Because A23187 began to precipitate when it exceeded 0.8 µg/50 µl gel, 
we chose not to test concentrations greater than this. 
-200
0
200
400
600
800
1000
1200
1400
Ba
Day 2
Ca
Day 2
Ba
Day 4
Ca
Day 4
IL
-1
β 
(p
g/
m
l g
el
)
 
 78 
 
  
Figure 4.2: A23187 delivered from calcium alginate gels injected laterally did not enhance inflammatory cytokine 
secretion. 50 µl calcium alginate gels with or without A23187 were injected laterally into mice. At day 2, gels were 
removed and analyzed for IL-1β and TNF-α. 
 
 
To determine if the injection site influenced the inflammatory response to alginate gels, 50 µl 
barium (4 mM) and calcium (48.8 mM) alginate gels were injected both laterally and medially into mice. 
At day 2, gels were removed and analyzed for IL-1β. It was observed that calcium alginate gels injected 
in the center of the back along the spine induced approximately 5 times more IL-1β secretion compared 
to calcium alginate gels injected laterally (Figure 4.3). There was also a slight increase in IL-1β secretion 
when barium alginate gels were injected medially versus laterally, but the results were not significant. 
 
 
Figure 4.3: Alginate gels injected medially into mice induced more IL-1β secretion than gels injected laterally. 50 
µl barium and calcium alginate gels were injected laterally or medially in mice. At day 2, alginate gels were 
removed and analyzed for IL-1β. n=4-12. *P≤0.05. 
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 Because alginate gels were injected into the body, which is an open system where calcium can 
diffuse freely in and out, we were highly interested in analyzing calcium concentrations within the gels 
over time. When analyzing gels injected medially, more than 50% of the calcium originally incorporated 
within calcium alginate gels was released within the first 12 hours (Figure 4.4); the Ca2+ concentration 
within the gels was maintained at a steady-state thereafter. Interestingly, the calcium concentration in 
barium alginate gels increased over time and also reached steady state by approximately 12 hours. It 
appeared that while calcium alginate gels acted as a calcium source, barium alginate gels acted as a 
calcium sink. 
 
 
Figure 4.4: Ca2+ concentration in gels reached steady state by 12 hours after medial injection. 50 µl barium (4 
mM) and calcium (48.8 mM) alginate gels were injected medially into mice. At various timepoints, alginate gels 
were removed and analyzed for Ca2+. 
 
In Chapter 2 it was demonstrated that increasing calcium crosslinker led to greater calcium 
release and enhanced inflammatory cytokine secretion by DCs in vitro. To determine if increasing 
calcium crosslinker could enhance cytokine secretion in vivo, 50 µl gels crosslinked with 4 mM barium or 
48.8, 75, or 100 mM calcium were injected medially into mice. On days 1 and 2, gels were harvested and 
analyzed for IL-1β. Contrary to in vitro results, increasing calcium crosslinker did not enhance IL-1β 
secretion in vivo (Figure 4.5). It was also observed that cytokine secretion decreased after day 1. 
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Figure 4.5: Increasing calcium crosslinker concentration did not enhance IL-1β secretion in vivo. 50 µl barium 
alginate gels or calcium alginate gels crosslinked with increasing concentrations of calcium were injected medially 
into mice. At days 1 and 2, gels were removed and analyzed for IL-1β. *P≤0.05. 
 
Since alginate gels injected medially were able to induce significantly greater IL-1β secretion, we 
next tested whether calcium alginate gels containing A23187 could enhance inflammatory cytokine 
secretion if injected in the center of the back rather than the side flank. Fifty or 100 µl alginate gels 
crosslinked with 48.8 mM CaSO4, and with or without 12 µg/ml A23187 (23 µM), were injected medially 
in the backs of mice and removed at day 2 for analysis. Rather than enhancing inflammatory cytokine 
secretion, delivering ionophore and increasing the gel volume decreased IL-1β and TNF-α expression 
(Figure 4.6).  
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Figure 4.6 (Continued): Increasing gel volume and delivering A23187 from calcium alginate gels injected medially 
did not enhance inflammatory cytokine secretion in vivo. Fifty and 100 µl calcium alginate gels, with or without 
12 µg/ml A23187, were injected medially into mice. At day 2, gels were removed and analyzed for IL-1β and TNF-α. 
Asterisks indicate that the condition is significantly different from the 50 µl calcium alginate control. *P≤0.05. 
 
 To determine if calcium alginate gels could enhance the effect of LPS as demonstrated in vitro, 
50 µl alginate gels crosslinked with 4 mM barium or 48.8 mM calcium, with or without 1 µg LPS, were 
injected medially into mice. After 24 hours, gels were harvested and analyzed for IL-1β. Consistent with 
in vitro data, calcium alginate gels (Ca) induced more IL-1β secretion compared to barium alginate gels 
(Ba), and LPS delivered from calcium alginate gels (Ca+LPS) more than quadrupled IL-1β secretion 
relative to LPS delivered from barium alginate gels (Ba+LPS) (Figure 4.7).  
 
Figure 4.7: Calcium alginate gels induce greater IL-1β secretion compared to barium alginate gels and enhanced 
LPS-induced IL-1β secretion in vivo. 50 µl barium and calcium alginate gels, with or without LPS, were injected 
medially into mice. After 24 hours, gels were harvested and analyzed for IL-1β secretion. *P<0.05. 
 
 
To get a more comprehensive analysis of other inflammatory mediators that calcium alginate 
gels induced from surrounding tissue, gels were multiplexed for 23 various cytokines and chemokines. 
Similar to DCs in Chapter 3, chemokines (MCP-1, MIP-1β, eotaxin, RANTES, MIP-1α and KC) were 
secreted in higher concentrations (Figure 4.8A). Interestingly, calcium gels alone upregulated IL-9 the 
most by ~9-fold (Figure 4.8B), and more than doubled the secretion of IL-1α, MIP-1β, IL-2, IL-1β, MCP-
1α, KC, and MIP-1α. The upregulation of IL-9 was particularly striking because it is commonly expressed 
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by CD4+ T-helper cells to stimulate proliferation and prevent apoptosis. Although several cytokines fell 
slightly below 1-fold upregulation (meaning that cytokine secretion was reduced with calcium-
crosslinked gels), t-tests comparing the two types of crosslinker showed that the P-values did not fall 
below 0.05 and thus, were not significant. LPS delivered from both barium and calcium alginate gels 
upregulated overall inflammatory cytokine secretion (with the greatest fold increases occurring for G-
CSF, IL-6, and MCP-1 for both types of gels) (Figure 4.8C). However, LPS delivered from calcium gels 
upregulated RANTES, IL-1β, MIP-1α, MIP-1β and IL-1α by approximately 3-5-fold more than LPS 
delivered from barium gels (Figure 4.8C). Overall, this data indicated that the calcium in calcium alginate 
gels promoted the secretion of a number of inflammatory mediators and enhanced inflammation 
induced by a TLR agonist in vivo, which is consistent with alginate in vitro data shown in Chapter 2. 
 
 
  
 
Figure 4.8  
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Figure 4.8 (Continued): Calcium alginate gels induce greater inflammatory cytokine secretion compared to 
barium alginate gels and enhanced LPS-induced inflammation in vivo. (A) The concentrations of cytokines and 
chemokines induced by barium and calcium gels with or without LPS were calculated. (B) The fold increase in 
cytokine secretion that calcium gels alone induced over barium gels alone was calculated. (C) The fold increases in 
cytokine secretion induced by barium gels with LPS and calcium gels with LPS over barium gels alone were 
calculated.  
 
4.4 Discussion 
 The results of these studies revealed that despite enhancing IL-1β secretion in vitro, A23187 
delivered from alginate gels did not enhance inflammatory cytokine secretion in vivo.  However, they 
demonstrated that the calcium released from calcium alginate gels significantly promoted inflammatory 
cytokine secretion and enhanced the effects of LPS in vivo.   
 In Chapter 3, it was shown that A23187 delivered from calcium alginate gels had a more potent 
effect on IL-1β secretion compared to both calcium alginate gels and A23187 alone. Thus, we postulated 
that A23187 delivered from alginate gels in vivo would induce greater inflammation than alginate gels 
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alone. However, contrary to in vitro data, A23187 delivered from alginate gels could not enhance 
inflammatory cytokine secretion in vivo. A past report showed that a 50 µl injection of 1 µM A23187 in 
DMSO in the footpad of mice was able to recruit lymphocytes and enhance vascular permeability at the 
site within the first 4 hours [1]. These effects dropped steeply by 8 hours and returned near baseline by 
24 hours. In another study, a 100 µl injection of 5 mM A23187 in DMSO into rats was able to locally 
recruit lymphocytes, which peaked at 2-3 hours after ionophore injection [2]. This suggests that 
although A23187 injected subcutaneously can have a measurable inflammatory effect on surrounding 
tissue, it loses its effectiveness within a few hours.  This is likely due to the ionophore diffusing away 
quickly through the tissue or degradation of the molecule, and possibly explains why the quick delivery 
of A23187 from alginate gels was unsuccessful. In our studies, ~15-30 µM of A23187 was delivered in 50 
or 100 µl alginate gels, which falls in the range of what has been previously used to recruit lymphocytes. 
It is possible that the ionophore was able to induce inflammation soon after injection, but had already 
returned to baseline by day 2 when the gels were analyzed, or that the levels of cytokines induced by 
A23187 fell below limits of detection. These results suggest that alternate materials should be 
considered as a delivery vehicle for ionophores to sustain their delivery for a more prolonged 
inflammatory effect. 
While A23187 did not enhance cytokine secretion in vivo, it was demonstrated that the calcium-
crosslinker itself was immunostimulatory. Similar to calcium release profiles in vitro, the majority of the 
calcium was released within the first few hours. An interesting finding was that the location of the 
injection altered the magnitude of cytokine secretion. Alginate gels injected down the center of the 
mouse’s back induced up to 5 times more inflammatory cytokine secretion compared to gels injected in 
the side flanks. Perfusion varies between tissues, which may explain why the ability of calcium alginate 
gels to act as an immunostimulatory source was highly dependent on the location of alginate 
implantation [7]. Although a burst release of calcium occurred within the first 6 hours, after which the 
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calcium concentration in gels remained constant, cytokines could be detected within the gels for at least 
4 days. It is possible that the alginate gels sequester cytokines induced by the burst release of calcium, 
but slowly release these cytokines as inflammation subsides, accounting for the drop in IL-1β seen after 
day 1. Consistent with results seen in vitro, calcium and LPS released from alginate gels had a synergistic 
effect and activated the most inflammatory cytokine secretion observed in vivo. Aside from IL-1β, strong 
upregulations in other inflammatory cytokines and chemokines were observed, which could be pursued 
further in future studies. 
The results of this study confirmed that the calcium used to crosslink alginate gels was released 
in vivo and stimulated the local secretion of inflammatory cytokines and chemokines. Furthermore, 
calcium released from the gels enhanced signaling induced by LPS. This data strongly suggests that 
future work with calcium-crosslinked alginate gels should take into account the stimulatory effect of 
calcium when using this material for tissue engineering and drug delivery, and provides convincing 
evidence that calcium signaling can be harnessed in vivo to promote inflammation.  
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Chapter 5 
Conclusions, Implications and Future Work 
 
5.1 Conclusions 
Given the importance of calcium signaling in dendritic cell activation and the ability of 
biomaterials to specifically target dendritic cells in vivo for immunotherapy, we hypothesized that a 
biomaterial-based approach could be used to target calcium signaling in DCs in vivo to enhance their 
activation. The first sub-hypothesis was that the calcium used to crosslink alginate gels could activate 
DCs in vitro; the second sub-hypothesis was that calcium ionophore A23187 could be delivered from 
biomaterials to activate DCs in vitro; and the third sub-hypothesis was that calcium used to crosslink 
alginate gels and/or controlled delivery of A23187 could increase local inflammation in vivo. We found 
that both the calcium released from calcium alginate gels and A23187 matured DCs and enhanced TLR-
induced inflammatory cytokine secretion in vitro. Although we were unable to effectively deliver A23187 
in vivo, calcium alginate gels injected subcutaneously were able to upregulate a number of inflammatory 
cytokines and chemokines relative to barium alginate gels. Likewise, the inflammatory effects of LPS on 
surrounding tissue were enhanced when LPS was delivered from calcium alginate gels versus barium 
alginate gels. Thus, we confirmed that the calcium crosslinker in alginate gels could activate DCs, and 
provided a proof-of-principle that calcium signaling could be harnessed in vivo to enhance the immune 
response. Not only does this work impact the future of biomaterial design, but it may also enhance our 
understanding of DC biology. 
 
5.2 Implications and Future Work 
 Based on the results presented in this thesis and previously published work, several implications 
can be drawn. These include expanding the ideas in this thesis to harness calcium signaling in other 
white blood cell types, taking into greater consideration the effects of calcium when using calcium 
 88 
 
alginate gels for biomedical applications, improving the delivery of A23187 to DCs and other cell types in 
vivo, and finally, extending this work to other ionophores, such as monensin.  
Alginate gels are commonly used for biomedical applications because they can encapsulate cells 
and drugs under physiological conditions and can be tailored to have different mechanical properties 
and degradation rates depending on the application. Here, we show that calcium, the most common 
ionic crosslinker used to crosslink alginate, can mature DCs, which should be taken into consideration 
when using this material for biological applications. Aside from DCs, many other leukocytes are heavily 
dependent on calcium signaling to carry out their effector functions and could potentially be sensitive to 
the calcium released from alginate gels [1]. For instance, it has been demonstrated that mast cells and 
neutrophils, important cells of the innate immune system, require calcium for degranulation, and that T 
cells require calcium signaling for the production of IL-2 and IL-4 [2-4]. Calcium’s importance in the 
proper functioning of the immune system can be underscored by the fact that a single missense 
mutation in the gene encoding CRAC causes severe combined immunodeficiency in humans [2]. Because 
of calcium’s importance in immune cell function, it has been proposed that calcium channels and 
calcium signaling pathways are promising therapeutic targets to control immune cell behavior [2, 4-7]. In 
Chapter 2, we also suggested that calcium alginate gels could potentially activate the inflammasome, 
which could have important implications in the field of vaccination. Thus, if using alginate gels for 
vaccination purposes, having calcium in the gels may be advantageous, but if trying to minimize 
inflammation, barium alginate gels may be recommended instead.   
Although the majority of studies utilizing calcium alginate gels for biomedical purposes have not 
examined the effects of calcium crosslinker, evidence in some studies indicates that it contributed to the 
outcome. As alluded to earlier, in a study where activated dendritic cells were delivered in calcium-
crosslinked alginate gels to reduce tumor size in mice, calcium alginate gels alone seemed to have a 
slight therapeutic effect. Consequently, it would be interesting to see if replacing the calcium with 
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barium would reduce vaccine efficacy [8]. Also mentioned earlier was that calcium-crosslinked alginate 
gels had a positive effect on angiogenesis in a mouse hindlimb ischemia model [9]. Although not 
statistically significant, alginate alone appeared to increase blood vessel density over untreated animals 
and animals injected with a bolus dose of vascular endothelial growth factor (VEGF). It is possible that 
the calcium in the gels promoted the secretion of endogenous pro-angiogenic factors from immune 
and/or non-immune cells leading to enhanced blood vessel formation. This could be easily tested by 
repeating barium and calcium alginate experiments described in this thesis but assaying for pro-
angiogenic factors instead. Lastly, alginate has been used for decades in the management of acute and 
chronic wounds, although its exact molecular and cellular effects are not well-understood. A recent 
paper found that alginate promoted keratinocyte differentiation, which is critical for wound healing, and 
that this was due to the calcium released by the alginate [1]. This could potentially explain the benefits 
of using alginate in wound dressings. These examples illustrate that it is important to characterize the 
effects that the calcium crosslinker has on other leukocytes and non-immune cells both in vitro and in 
vivo.  
Despite the use of A23187 to enhance the activation of DCs in vitro and the injection of A23187 
to transiently recruit lymphocytes in vivo [10, 11], there has yet to be a study aimed at delivering the 
ionophore in vivo to sustain a potent and lasting immune response for immunotherapy. In our studies, 
A23187 delivered from calcium alginate gels did not enhance inflammatory cytokine secretion over 
calcium alginate gels alone in vivo (even though this was observed in vitro), and this was likely due to the 
quick release of ionophore from the material and its short-lived bioactivity. Additionally, although 
calcium alginate gels alone had an immunostimulatory effect, it was unclear what cell types were being 
affected by the calcium. For a more sustained and direct immunostimulatory effect, materials that can 
release ionophore over longer time periods or that can deliver payloads directly to dendritic cells will 
likely be more promising. In Chapter 3, porous PLG scaffolds encapsulating A23187 were described with 
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the idea that they could also contain GM-CSF and antigens to recruit and program DCs. More work could 
be done to characterize A23187 release from these scaffolds and to tune the PLG degradation rate (i.e. 
change the molecular weight and/or lactic to glycolic acid monomer ratio) for optimum release kinetics 
[12]. Another benefit of using PLG, aside from it being able to sustain the release of A23187, is that the 
material itself can be immunostimulatory [13-15]. Alternatively, different polymers could be selected to 
deliver A23187. One important consideration to keep in mind is that other local cells (both immune and 
non-immune) could be affected by the A23187 released from scaffolds, which may be desirable or 
undesirable. 
Another approach would be to develop nanoparticles that can target A23187 to dendritic cells 
either in the periphery or in the lymph nodes. Nanoparticles could be a better approach as they can be 
targeted to specific cells (see Chapter 1) and release ionophore within the cell after internalization 
resulting in a more potent and specific effect. Particles less than ~100 nm are able to enter the 
lymphatics and be taken up by lymph node DCs, whereas larger nanoparticles tend to stay at the site of 
injection and be taken up by local DCs patrolling the area [16]. When the particle reaches the desired 
location and/or is taken up by DCs, it is important that the payload, in this case the ionophore, is 
released. This can be achieved by fabricating nanoparticles made of quickly degrading PLG/PLA polymers 
[17, 18] or a number of other materials that have been engineered to exploit the acidic, enzymatic and 
reductive environment of the endolysosome [19-23]. Interestingly, calcium phosphate nanoparticles 
(e.g. hydroxyapatite) have been commonly studied as vaccine delivery vehicles, since they have been 
shown to have potent adjuvant effects [24-26], and other studies have found that calcium phosphate 
crystals can activate the NLR3P inflammasome [27, 28]. Whether these effects are due to the calcium 
specifically or another property of the material is unclear, but these previous findings could make 
calcium phosphate an interesting and attractive choice for A23187 delivery. 
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To screen for optimal materials and dosage to deliver A23187, preliminary studies could be 
performed in vitro using 2D cultured DCs. It was previously shown that a 50 µl injection of a 1 µM 
A23187 solution (526 ng/ml), which is close to what was used to activate DCs in vitro (400 ng/ml), was 
able to induce lymphocyte infiltration in vivo [10]. These values can provide a starting point to help 
optimize the dose and release of A23187 from both scaffolds and nanoparticles. 
Although our attention has been focused on targeting A23187 to DCs, other ionophores specific 
for Ca2+ or other ions (e.g. ionomycin or monensin) could be targeted to DCs and other cell types as a 
useful tool to control cellular functions in vivo. For example, ionomycin, another calcium ionophore, is 
already a commonly used experimental tool to stimulate T cells in vitro. In this thesis, we showed that 
monensin, a sodium ionophore, downregulated DC maturation markers compared to control cells, which 
suggests that it could potentially be used for immunosuppression. Monensin is commonly used to for 
intracellular cytokine staining because it disrupts the function of the Golgi apparatus trapping proteins 
within the cell. In instances where there is an undesirable immune response, as in the cases for allergy 
and autoimmunity, it could be useful to deliver monensin to specific T and B cells to suppress the 
progression of the disease. For transplantation, monensin delivery to DCs could be useful to minimize 
cross-presentation of tissue antigens and rejection of grafted tissue. Research studying mechanisms of 
immune tolerance and ways to induce regulatory responses has grown considerably over the past few 
years [29-32], and the controlled delivery of monensin could provide immunologists and bioengineers 
with a new tool to suppress the immune response.  
The power of ion signaling to control cell fate is evident, and with the existence of a number of 
ionophores and an array of biomaterials that could be used to deliver them, one can begin to imagine 
the possibilities. If successful, the regulation of ion signaling in vivo may prove to have significant utility 
in the field of medicine. 
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Appendix 1 
Effectiveness of an Implantable Cancer Vaccine in the C1498 Mouse Leukemia 
Model 
 
A1.1 Introduction 
The PLG in situ cell programming system described earlier in this thesis has been successful in 
reducing tumor growth and enhancing survival in mouse models of melanoma and glioma [1-3]. We 
hypothesized that we could apply this system in a mouse model of leukemia to reduce tumor burden 
and increase mouse survival. If successful, this could be a potential approach to treat leukemia patients 
in remission and prevent relapse caused by minimal residual disease. To test this, we chose to use the 
C1498 cell line, a myeloid leukemia line derived from C57BL/6J mice, because it can be easily injected 
into C57 mice to induce leukemia [4-6]. We vaccinated C57 mice with anti-C1498 scaffolds (with or 
without A23187), challenged them with C1498 cells two weeks later, and determined vaccine efficacy by 
monitoring mouse survival. 
 
A1.2 Materials and Methods 
Cell culture 
C1498 cells (ATCC, Manassas, VA) were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM) (Life Technologies) containing 10% heat-inactivated FBS, 100 U/ml penicillin, and 100 µg/ml 
streptomycin. 
 
Survival Studies 
 PLG scaffolds (8.5 mm diameter) were fabricated according to standard methods in the lab [1, 
2]. They contained 18 mg of PLG microspheres, ~2 µg of GM-CSF, 107 C1498 tumor cell lysates, and 300 
µg of condensed CpG. To test the effects of A23187, A23187 was incorporated into the scaffolds by 
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adding it to the PLG oil phase during microsphere fabrication so the final concentration (assuming 89% 
encapsulation efficiency) equaled 10 µg/scaffold. Blank and drug-loaded scaffolds were implanted 
subcutaneously in the backs of C57BL/6J mice, and two weeks later they were injected with 2x106 C1498 
cells/100 µl PBS via the tail vein. Survival was monitored over several weeks.   
 
DC Recruitment Studies 
For comparison of DC recruitment between blank and drug-loaded scaffolds, scaffolds 
containing GM-CSF only were fabricated as above. After 7 days of implantation, scaffolds were removed, 
cut into small pieces, placed in tubes containing 10 ml of type IV collagenase (250 U/ml PBS) 
(Lot#40E11931) (Worthington Biochemical, Lakewood, NJ), and incubated in a 37°C water bath for 30 
minutes with vortexing every 10 minutes. Dissociated cells were strained through a 40 µm cell strainer, 
washed in stain buffer, and stained with APC-conjugated anti-mouse CD11c for analysis by flow 
cytometry.  
 
A1.3 Results 
 Drug-loaded scaffolds containing C1498 lysates were able to enhance survival of mice 
challenged with C1498 leukemia by roughly one week when compared to blank scaffolds (Figure A1.1A). 
In a second trial, the vaccine was able to extend survival longer than one week for one mouse and 
completely cured another mouse (Figure A1.1B). Although A23187 has been shown to enhance DC 
activation, scaffolds containing A23187 actually reduced survival compared to scaffolds without it 
(Figure A1.1B). 
  
 98 
 
 
Figure A1.1: Implantable cancer vaccine enhanced survival in C1498 leukemia model while A23187 reduced its 
efficacy. (A) Blank and drug-loaded PLG scaffolds were implanted subcutaneously in mice. 2 weeks later, mice 
were challenged with C1498 leukemia cells and survival was monitored over several weeks. n=6. (B) Drug-loaded 
scaffolds containing 10 µg of A23187 were tested for their ability to enhance survival. n=5. 
 
 When analyzing the effect of GM-CSF on DC recruitment, we found that scaffolds containing 
GM-CSF enhanced overall cell numbers (Figure A1.2A) but decreased the percentage of CD11c positive 
cells (Figure A1.2B). When the number of DCs recruited to the scaffolds was calculated, it was 
determined that although scaffolds containing GM-CSF recruited more cells, the number of DCs was 
approximately the same as blank scaffolds accounting for the decreased percentage of CD11c positive 
cells (Figure A1.2C). 
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Figure A1.2 (Continued): Scaffolds containing GM-CSF recruited more cells overall, but the number of recruited 
DCs remained the same. (A) After 7 days of implantation, blank scaffolds or scaffolds containing GM-CSF were 
removed and analyzed for total cell number. (B) Cells isolated from scaffolds were stained with CD11c and 
analyzed by flow cytometry. (C) The number of DCs recruited to each scaffold was calculated based on the data in 
(A) and (B). Data is presented as mean ± standard deviation. *P<0.05; **P<0.001. 
 
A1.4 Conclusion 
 The PLG in situ programming system was successful at enhancing survival in the C1498 mouse 
model of myeloid leukemia. Although A23187 has been shown to enhance DC activation in vitro, it 
reduced vaccine efficacy in this in vivo model. It is possible that interactions between A23187 and other 
components of the scaffold reduced its overall efficacy, or that the amount of ionophore encapsulated 
in the scaffolds was so great that they destabilized cellular membranes leading to toxicity. Further 
experiments would be needed to determine the cause. Lastly, although GM-CSF enhanced overall cell 
recruitment to the scaffold, it did not significantly enhance CD11c+ DC recruitment. 
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Appendix 2 
Differentiating Myeloid Leukemia Cells into Antigen Presenting Cells In Situ for 
Anti-Leukemia Therapy 
 
A2.1 Introduction 
This thesis demonstrated that A23187 could mature DCs and enhance TLR-induced DC 
activation. In addition to maturing DCs, A23187 has been used along with phorbol 12-myristate 13-
acetate (PMA) to differentiate patients' myeloid leukemia cells into APCs ex vivo. The hope has been 
that these leukemia-derived APCs can be re-introduced into the patient while they are in remission, 
home to the lymph nodes, and present leukemia antigens to T cells to generate anti-leukemia responses 
that would prevent relapse caused by minimal residual disease (MRD) [1-4]. However, critical issues with 
this procedure (and ex vivo manipulation, in general) are that primary tumor cells are difficult to isolate 
and culture, and the majority of cells re-injected into the patient do not home to the lymph nodes [5, 6]. 
This may explain why this approach to combat myeloid leukemia has not been successful in the clinic [7]. 
To address issues associated with the ex vivo manipulation of leukemia cells, we hypothesized that we 
could apply the PLG in situ programming system described in this thesis to recruit and differentiate 
myeloid leukemia cells into APCs using A23187 and/or PMA for anti-leukemia therapy [8, 9]. To 
demonstrate proof-of-principle, we needed to choose a model myeloid leukemia line that could be 
differentiated into an APC phenotype using A23187 and/or PMA and could be recruited with 
chemoattractants. We chose to test the human myeloid leukemia cell line HL-60, which has been 
previously shown to engraft well in nude mice and to differentiate into an APC phenotype with exposure 
to A23187 and PMA [2, 10]. We also tested the C1498 cell line because it easily engrafts in C57BL/6J 
mice. In the following studies, we wanted to verify that HL-60 and C1498 cells could be differentiated by 
A23187 and/or PMA in vitro and that we could establish an in vivo HL-60 nude mouse model. We also 
tested the bacterial peptide N-Formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP) as a recruiting factor 
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in vitro, since it has been shown to be a strong chemoattractant for HL-60, and then assessed its 
encapsulation and release from PLG scaffolds in vitro [11, 12]. 
 
A2.2 Materials and Methods 
Cell Culture 
HL-60 cells (ATCC) were cultured in Iscove’s Modified Dulbecco’s Medium (IMDM) (Life 
Technologies) containing 20% heat-inactivated FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin. 
C1498 cells were cultured in DMEM containing 10% heat-inactivated FBS, 100 U/ml penicillin, 
and 100 µg/ml streptomycin. 
 
Differentiation Assays 
HL-60 cells were resuspended at a concentration of 333,333 cells/ml of control IMDM or IMDM 
containing 400 ng/ml A23187 and/or 10 ng/ml PMA (Sigma-Aldrich). 106 cells (3 ml) of each condition 
were plated in 6-well plates. After 20-24 hours, differentiated cells were collected and stained with PE-
conjugated anti-human CD80 (BioLegend, San Diego, CA), APC-conjugated anti-human CD86 
(BioLegend), and Pacific Blue™-conjugated anti-human MHC class I (human leukocyte antigen (HLA) – A, 
B, C) (BioLegend). Fluorescence was quantified using an LSR II or LSR Fortessa™ flow cytometer. 
Photomicrographs of cells were taken with an Olympus IX81 inverted microscope. 
For C1498 differentiation, 106 cells/1.5 ml were plated in 6-well plates. After 1 hour of 
incubation, 1.5 ml of control DMEM or DMEM containing A23187 and/or PMA was added to each well 
so that the final concentrations equaled 400 ng/ml A23187 and/or 10 ng/ml PMA. After 20-24 hours, 
cells were scraped from each well and stained with PE-conjugated anti-mouse CD86, APC-conjugated 
anti-mouse CD80, and FITC-conjugated anti-mouse MHC class I (eBioscience). Fluorescence was 
quantified as above using flow cytometry.  
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Migration Assays 
 To confirm that fMLP was a strong chemoattractant of HL-60, 0.6 ml medium containing 10-8 M 
GM-CSF, CCL21, or fMLP were plated in 24 well plates. Transwells (Corning, Lowell, MA) containing 5 µm 
size pores were inserted into each well, and 500,000 cells in 0.3 ml medium were pipetted into each 
transwell. At 2, 4 and 6 hours, the transwells were removed, and cells that had migrated through the 
transwell were counted with a Z2 particle counter. To test optimum fMLP concentration, a similar 
experiment was repeated, but this time medium contained of 10-9, 10-8 or 10-7 M fMLP and cells were 
collected after 1 hour. 
 To determine if fMLP could induce differentiation of HL-60 cells into APCs, cells were cultured in 
control medium or medium containing 10-8 M fMLP or 400 ng/ml A23187 (a positive control) for 20-24 
hours. Cells were then stained with APC-conjugated anti-human CD86, Pacific Blue™-conjugated anti-
human MHC class I, and FITC-conjugated anti-human CCR7 (eBioscience) and analyzed using flow 
cytometry.   
 
Scaffold Fabrication, Encapsulation Efficiency, and Release Assays 
 PLG scaffolds (8.5 mm diameter) containing fMLP were fabricated using methods described 
previously [8, 9]. The amount of fMLP added to the PLG/oil phase during microsphere fabrication was 
such that the final amount in each 18 mg scaffold equaled 1.8 mg fMLP (assuming 100% encapsulation 
efficiency). To analyzed fMLP encapsulation efficiency and release, the same protocol described in 
Chapter 3 to determine A21387 release was used. 
 
HL-60 Induction in Nude Mice  
To develop an HL-60 in vivo mouse model to test the in situ programming system, 6 week-old 
NU/J mice (Jackson Laboratory) were injected with 30x106 HL-60 cells in a 150 µl volume via the tail 
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vein. At 1, 2, 4, and 6 weeks, blood was collected and mice were sacrificed so that their inguinal lymph 
nodes and spleens could be harvested and analyzed for HL-60. For blood collection, mice were 
anesthetized with isoflurane, and 300 µl of blood was collected through the orbital sinus with capillary 
tubes. To prevent clotting, blood was emptied into polypropylene tubes containing 50 µl of 600 USP/ml 
heparin solution. After blood collection, mice were sacrificed so their lymph nodes and spleens could be 
harvested. For HL-60 detection in blood, 100 µl of each blood sample was pipetted into 15 ml tubes, and 
1 µg of Pacific Blue™-conjugated anti-human MHC class I in 10 µl of stain buffer was added. After 30 
minutes of incubation on ice, red blood cells (RBCs) were lysed with ammonium-chloride-potassium 
(ACK) lysing buffer. Remaining cells were washed and resuspended in staining buffer for analysis. 
Spleens were mashed with a back of a syringe and lymph nodes were dissociated using needles in a 
small Petri dish containing HBSS+. Cells were passed through a 70 µm cell strainer, and RBCs in spleen 
samples were lysed using ACK lysing buffer. Organ samples were then washed and stained with Pacific 
Blue™-conjugated anti-human MHC class I antibody for flow cytometry analysis. 
To improve HL-60 engraftment, mice were injected intraperitoneally (I.P.) with 3 mg 
cyclophosphamide/100 µl PBS 3 days prior to HL-60 injection via the tail vein. At 3, 6, and 7 weeks after 
leukemia induction, blood, inguinal lymph nodes, and spleens were harvested for HL-60 analysis as 
described above. 
 
A2.3 Results 
 A23187 was found to upregulate HL-60 expression of CD80, CD86, and MHC class I (Figure 
A2.1A). Although results were less striking, PMA (which in addition to A23187 has also been shown to 
induce HL-60 cells into an APC phenotype [2]) was also able to increase CD80 and CD86. The 
combination of PMA and A23187 did not seem to significantly enhance differentiation compared to 
A23187 alone. A23187 also increased CD86 expression by C1498 cells, but overall, induced less C1498 
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differentiation compared to HL-60 cells (Figure A2.1B). Thus, A23187 and HL-60 cells were used for the 
remainder of the study. Interestingly, it was observed that A23187 caused HL-60 cells to form dendrites 
characteristic of activated DCs, while PMA caused them to acquire a more fibroblastic-like appearance 
(Figure A2.1C). The combination of PMA and A23187 caused cells to cluster into colonies. 
 
 
 
Figure A2.1: A23187 strongly induced HL-60 cells to acquire an APC phenotype. (A) HL-60 cells were cultured 
overnight in control medium or medium containing A23187 and/or PMA. Cells were stained for CD80, CD86 and 
MHC class I to gauge differentiation. n=3. Data is presented as mean ± standard deviation. (B) C1498 cells were 
cultured overnight with A23187 and/or PMA and analyzed as above. n=1. (C) Photomicrographs of HL-60 cells were 
taken 24 hours after culture with control or differentiation medium. 
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 fMLP has been shown to be a potent chemoattractant of HL-60. We found that compared to 
GM-CSF and CCL21, strong chemoattractants of myeloid cells, fMLP was able to induce more cell 
migration (Figure A2.2A) with an optimum concentration of 10-8 M (Figure A2.2B). Unlike A23187, fMLP 
was not able to induce HL-60 differentiation (Figure A2.2C). 
 
   
 
Figure A2.2: fMLP was a potent HL-60 chemoattractant. (A) 10-8 M of GM-CSF, CCL21, and fMLP were tested for 
their ability to attract HL-60 cells using a transwell migration assay. n=3. (B) Transwell migration assays were also 
used to determine the optimum fMLP dose. n=3. (C) HL-60 cells were cultured with fMLP overnight and stained for 
CD86, CCR7, and MHC class I to determine if it could induce HL-60 differentiation into an APC phenotype. n=3. 
Data is presented as mean ± standard deviation. 
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LC-MS was used to test the release of fMLP from PLG scaffolds. Using the LC-MS protocol 
described in Chapter 3, fMLP was found to elute at approximately 2.95 minutes (Figure A2.3A) and have 
a mass of 438.2 g/mol (Figure A2.3B). The lower limit of detection was ~0.001 mg/ml. 
 
 
 
                                                          
 
Figure A2.3: fMLP was detected with LC-MS. (A) Chromatogram of 1 mg/ml fMLP. fMLP eluted at ~2.95 minutes. 
(B) Mass spectrum of fMLP. 
 
 Unlike A23187 (see Chapter 3), fMLP had a much lower encapsulation efficiency of 2-8%, 
meaning that of the original 1.8 mg of fMLP used for scaffold fabrication, only 40-150 µg was actually 
encapsulated. A signficant amount (~66 µg) was released during the porogen leach, and the remainder 
was released within the first day of the release study (Figure A2.4). 
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Figure A2.4: fMLP released quickly from PLG scaffolds. Cumulative release of fMLP from PLG scaffolds. fMLP was 
detected using LC-MS. n=3. Data is presented as mean ± standard deviation. 
 
 To establish an in vivo leukemia model in which the in situ programming scaffold could be 
tested, nude mice were injected via the tail vein with 30x106 HL-60 cells. To determine whether HL-60 
cells were able to persist and cause disease, peripheral blood, inguinal lymph nodes, and the spleens of 
mice were analyzed at 1, 2, 4, and 6 weeks for HL-60 infiltration. At each of the timepoints, organs were 
negative for HL-60. However, between 5-7 weeks, palpable tumors began to grow in some mice, 
particularly on the back of the neck (Figure A2.5). Cells isolated from these tumors stained ~96% positive 
for HLA indicating that they consisted mainly of HL-60 cells. Aside from tumor growth, mice appeared 
otherwise healthy. 
 
 
 
Figure A2.5: Nude mice injected with HL-60 cells via the tail vein developed tumors at 5-7 weeks. Photograph of 
a mouse with an HL-60 tumor on the back of the neck.  
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In a previous study, it was reported that cyclophosphamide administration aided in HL-60 
engraftment in nude mice [10]. To promote HL-60 engraftment, mice were given 3 mg 
cyclophosphamide injections 3 days prior to HL-60 induction. HL-60 infiltration of organs was then 
monitored at 3, 6, and 7 weeks. Unlike the reported results, we could not detect HL-60 in the peripheral 
blood or in any of the harvested organs, and no solid tumor formation was observed.  
 
A2.4 Conclusion 
 HL-60 myeloid leukemia cells were strongly induced by A23187 to acquire an APC phenotype 
and were strongly attracted by the bacterial derived chemoattractant fMLP. However, A23187 and fMLP 
release need to be optimized (for both concentration and release kinetics) in order for the leukemia cells 
to be significantly affected in vivo. This could be accomplished by tuning the PLG (such as its degradation 
rate) or by choosing alternative materials to deliver the factors.  
In this study, HL-60 cells were not able to properly engraft in nude mice, and it is likely that mice 
with a more severe form of immunodeficiency will be necessary to establish an HL-60-mediated 
leukemia model. Ultimately, an immunocompetent mouse will be needed to test the ability of myeloid 
leukemia-derived APCs to induce adaptive anti-leukemia immune responses and reduce leukemia 
progression. 
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Appendix 3 
Effect of Extracellular Matrix on Dendritic Cell Maturation 
 
A3.1 Introduction  
It is widely appreciated that cell-matrix interactions can play a critical role in cell phenotype and 
behavior [1, 2]. For example, integrin signaling has been shown to converge with immunoreceptor 
signaling and plays an important role in leukocyte effector functions [3]. Specifically, extracellular matrix 
(ECM) proteins have been shown to influence DC development and phagocytosis, which in turn 
influence the quality of T cell stimulation [4-6]. To verify that ECM proteins could influence DC 
maturation, we cultured bone marrow-derived DCs overnight on increasing densities of fibronectin or 
laminin, as well as encapsulated in calcium-crosslinked alginate matrices modified with increasing 
densities of RGD peptide, in the presence or absence of TLR-ligands. Supernatants were analyzed for the 
inflammatory cytokine IL-12p70 to gauge maturation. 
 
A3.2 Materials and Methods 
Fibronectin and Laminin Studies 
50 µl of sterile human fibronectin (hFN) (Sigma-Aldrich), mouse fibronectin (mFN) (Innovative 
Research, Novi, MI), or mouse laminin (mLN) (BD Biosciences) in carbonate buffer (15 mM Na2CO3 
(Sigma-Aldrich), 35 mM NaHCO3 (Sigma-Aldrich), pH 9.4) was plated onto non-tissue culture treated 96-
well plates overnight at 4°C so that the plating density of each protein equaled 0, 10, 100, 1,000, or 
10,000 ng/cm2. The next day, the solutions were aspirated, and 200 µl of a sterile solution of 1 mg/ml 
Pluronic F-127 (P127) (Sigma-Aldrich) in PBS was plated per well for 1 hour at room temperature to 
block non-specific binding. To control for P127, unmodified wells lacking both ECM protein and P127 
were included in the experiment. Wells were washed twice with PBS and 100,000 DCs/180 µl of R10 
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medium were plated per well (see Chapter 2 for protocol on generating primary bone-marrow derived 
DCs). One hour or 18 hours after attachment, cells were pulsed with 20 µl of LPS or CpG such that the 
final concentration equaled 100 ng/ml or 5 µM, respectively. After 20-24 hours, supernatants were 
collected and frozen at -20°C for IL-12p70 analysis by Quantikine ELISA.  
 
DC Encapsulation in RGD-Modified Alginate Matrices 
MVG alginate was modified with increasing amounts of RGD peptide (Peptides International, 
Louisville, KY), using standard methods developed in the lab [7], so that the degree of substitution per 
alginate chain was 2, 10, or 20. DCs were encapsulated in RGD-modified MVG alginate discs as described 
in Chapter 2 and placed in medium. After one hour of incubation at 37°C and 5% CO2, cells were 
activated with CpG such that the final concentration equaled 5 µM. To compare encapsulation time on 
DC activation, cells were encapsulated in MVG alginate beads as described in Chapter 2, and after 1 or 
18 hours after encapsulation, were pulsed with 5 µM CpG. After 24 hours, supernatants were collected 
and analyzed for the DC maturation cytokine IL-12p70. 
 
A3.3 Results 
To determine if fibronectin density could influence DC activation, DCs were cultured on 
increasing densities of human and mouse fibronectin blocked with Pluronic F127, and one hour later, 
were stimulated with control medium, LPS or CpG. DCs plated on hFN without TLR stimulation did not 
secrete detectable cytokine (data not shown), but DCs activated with LPS or CpG secreted increasing 
concentrations of IL-12p70 with increasing hFN density (Figure A3.1A). Interestingly, DCs plated on mFN 
without TLR stimulation and DCs plated on mFN with CpG activation secreted increasing concentrations 
of IL-12p70 with increasing mFN density, but there was no obvious trend with LPS (Figure A3.1B). 
Overall, the data strongly suggested that increasing fibronectin density promoted DC activation in vitro. 
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Figure A3.1: Effect of ECM protein density on DC activation (DCs plated 1 hour before activation). (A) DCs were 
plated onto wells with increasing densities of hFN blocked with Pluronic F127 (P127). As a control, DCs were plated 
onto unmodified wells (No P127). One hour after plating, DCs were stimulated with control medium (not shown), 
LPS, or CpG. After 20-24 hours of stimulation, supernatants were collected and analyzed for IL-12p70 by ELISA. 
n=3. (B) DCs were plated onto wells with increasing densities of mFN and stimulated with control medium (Con), 
LPS, or CpG as above. After 20-24 hours of stimulation, supernatants were collected and analyzed for IL-12p70 by 
ELISA. n=3. Data is presented as mean ± standard deviation. 
 
 
 It has been shown that when DCs mature they become less responsive to subsequent 
stimulation. Given that mFN alone was able to induce IL-12p70 secretion, we wanted to establish 
whether DC plating on ECM proteins caused DCs to mature and lose their ability to be stimulated over 
time. The above experiments were repeated except DCs were stimulated 18 hours after plating instead 
of 1 hour. DCs plated on hFN and stimulated with LPS secreted increasing concentrations of IL-12p70 
with increasing hFN density, but when DCs were stimulated with CpG, IL-12p70 secretion seemed to 
peak at 102 ng/cm2 (without LPS stimulation, IL-12p70 was undetectable (data not shown)) (Figure 
A3.2A). DCs plated on mFN without TLR stimulation secreted increasing concentrations of IL-12p70 with 
increasing mFN density, but when DCs were stimulated with LPS or CpG, IL-12p70 secretion peaked at 
102 ng/cm2 (Figure A3.2B). Lastly, DCs plated on mLN secreted increasing concentrations of IL-12p70 
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with increasing mLN density when stimulated with LPS (without LPS stimulation, IL-12p70 was 
undetectable (data not shown)) (Figure A3.2C). Taken together, these results indicate that delaying 
activation of bone-marrow derived DCs in vitro may reduce their ability to be activated depending on 
the ECM protein, the concentration that the protein is plated, and the TLR agonist. 
 
  
   
 
Figure A3.2: Effect of ECM protein density on DC activation (DCs plated 18 hours before activation). (A) DCs were 
plated onto wells with increasing densities of hFN blocked with Pluronic F127 (P127). As a control, DCs were plated 
onto unmodified wells (No P127). Eighteen hours after plating, DCs were stimulated with control medium (not 
shown), LPS, or CpG. After 20-24 hours of stimulation, supernatants were collected and analyzed for IL-12p70 by 
ELISA. n=3. (B) DCs were plated onto wells with increasing densities of mFN and stimulated with control medium, 
LPS, or CpG as above. After 20-24 hours of stimulation, supernatants were collected and analyzed for IL-12p70 by 
ELISA. n=3. (C) DCs were plated onto wells with increasing densities of mLN and treated with control medium (data 
not shown) or LPS. After 20-24 hours of stimulation, supernatants were collected and analyzed for IL-12p70 by 
ELISA. n=4. Data is presented as mean ± standard deviation. 
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 Similar to the above 2D studies, we were interested in determining if 3D culture of DCs in 
calcium alginate gels caused them to lose their ability to be stimulated over time. DCs were 
encapsulated in alginate beads, and 1 hour or 18 hours after encapsulation were stimulated with control 
medium or CpG. Control DCs did not secrete detectable IL-12p70 (data not shown). However, we found 
that culturing DCs in alginate gels for 18 hours reduced their ability to secrete IL-12p70 in response to 
CpG (Figure A3.3A).  
 To determine whether matrix protein density could influence DC activation in 3D, DCs were 
encapsulated in alginate discs with increasing densities of RGD peptide and treated with control medium 
or CpG 1 hour after encapsulation. DCs cultured in control medium did not secrete detectable IL-12p70 
(data not shown), and unlike studies done on 2D TCPS, IL-12p70 secretion in 3D alginate matrices was 
not influenced by integrin-matrix interactions (Figure A3.3B).  
 
    
Figure A3.3: Effect of encapsulation time and RGD density on activation of DCs in alginate matrices. (A) After 1 
hour or 18 hours of encapsulation in calcium alginate beads, DCs were stimulated with control medium (not 
shown) or CpG. After 20-24 hours of stimulation, supernatants were collected and analyzed for IL-12p70 by ELISA. 
n=3. (B) After 1 hour of encapsulation in calcium alginate discs with increasing RGD densities, DCs were stimulated 
with control medium (not shown) or CpG. After 20-24 hours of stimulation, supernatants were collected and 
analyzed for IL-12p70 by ELISA. n=4. Data is presented as mean ± standard deviation.  
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A3.4 Conclusion 
 Increasing ECM protein density generally promoted IL-12p70 secretion when DCs were cultured 
on 2D surfaces. However, after 18 hours, DCs cultured on both 2D surfaces (depending on the ECM 
protein and its plating density) and within calcium alginate matrices tended to lose their ability to be 
stimulated. Because DCs easily mature after being manipulated and have a diminished capability of 
being activated after maturation, it is recommended that DCs be assayed soon after plating or 
encapsulation. The results of this study also suggest that DC behavior can be modulated by controlling 
DC-matrix interactions, which could be useful for biomedical applications. 
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Appendix 4 
Effect of Collagenase Type on Dendritic Cell CD11c Staining 
 
A4.1 Introduction 
 Various cell-surface antigens are susceptible to cleavage by trypsin, which is commonly found in 
collagenase used to digest tissues. When analyzing tissue-extracted cells for surface markers, it is 
important to choose collagenase type with caution, as any contaminating trypsin could cleave markers 
of interest. CD11c, a DC marker, is an example of a cell-surface protein that is cleavable by trypsin, and 
we hypothesized that exposing DCs to collagenase with higher trypsin content would lead to greater 
CD11c cleavage [1, 2]. To test this, we incubated bone-marrow derived DCs in collagenase type II and IV 
(the latter containing less trypsin) at 37°C for 15, 30 and 60 minutes, and analyzed the DCs for CD11c 
and CD86 using flow cytometry.     
 
A4.2 Materials and Methods 
Bone marrow-derived DCs were cultured as described in Chapter 2. On Day 10 of culture, LPS 
was added to the Petri dishes so that the final concentration equaled 100 ng/ml. After 24 hours, cells 
were collected and washed. 2x106 cells were pipetted into 15 ml tubes, spun, and resuspended in 250 
U/ml of collagenase type II (Lot#S9E11242) or type IV (Lot#40E11931) (Worthington) in PBS. Tubes were 
placed in a 37°C water bath and vortexed every 10 minutes. At 15, 30, and 60 minutes, cells were spun 
down, washed in stain buffer and stained with APC-conjugated anti-mouse CD11c or PE-conjugated anti-
mouse CD86 for analysis by flow cytometry. 
 
A4.3 Results 
 As hypothesized, we found that type II collagenase, which contained 1.23 u/mg of tryptic 
activity, reduced DC expression of CD11c significantly more than type IV collagenase, which contained 
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0.03 u/mg of tryptic activity. When digestion was allowed to occur for 30 minutes, CD11c staining 
decreased by approximately 5% and for 60 minutes decreased by 10%. CD86 was less affected by type II 
collagenase digestion (Figure A4.1). 
 
 
Figure A4.1: Type II collagenase significantly cleaved CD11c on bone marrow derived DCs. DCs were treated with 
type II and type IV collagenase for 15, 30, and 60 minutes at 37°C and stained for CD11c and CD86.  
 
A4.4 Conclusion 
 When digesting scaffolds and tissues for CD11c analysis, it is recommended that for optimum 
staining, type IV collagenase should be used instead of type II. 
 
A4.5 References 
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Appendix 5 
Optimal Temperature for Dendritic Cell CCR7 Staining 
 
A5.1 Introduction 
 It has been demonstrated that the anti-CCR7 4B12 antibody clone stains more brightly at 37°C 
than 4°C [1]. To confirm this, we stained bone-marrow derived DCs with the PE-Cy7-conjugated 4B12 
anti-CCR7 antibody at 4°C and 37°C and compared staining using flow cytometry. 
 
A5.2 Materials and Methods 
 Bone marrow-derived DCs were cultured as described in Chapter 1. On Day 10 of culture, LPS 
was added to the Petri dishes so that the final concentration equaled 100 ng/ml. After 24 hours, cells 
were collected, washed, and stained with APC-conjugated anti-mouse CD11c , PE-conjugated anti-
mouse CD86, and PE Cy7-conjugated anti-mouse CCR7 (Clone 4B12; eBioscience) at either 4°C or 37°C 
for analysis by flow cytometry. 
 
A5.3 Results 
 CCR7 staining was brighter when it was performed at 37°C rather than 4°C, while CD86 staining 
and CD11c staining were unaffected by staining temperature (Figure A5.1). 
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Figure A5.1: CCR7 (Clone 4B12) staining was brighter when performed at 37°C. CCR7, CD86 and CD11c staining 
were performed at 4°C (blue) and 37°C (black). 
 
A5.4 Conclusion 
 When performing CCR7 staining with antibody clone 4B12, it is recommended that staining be 
done at 37°C according to the manufacturer’s instructions.  
  
A5.5 References 
[1] eBioscience. Anti-Mouse CD197 (CCR7) PE-Cy7. Online. 2013 February. Available from 
URL: http://www.ebioscience.com/media/pdf/tds/25/25-1971.pdf. 
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Appendix 6 
General Staining Protocol for Flow Cytometry 
 
A6.1 Materials 
 
Stain buffer with BSA 
FC blocking antibody, staining antibodies, and isotype controls 
96-well non-TC U-bottom plate 
Multichannel pipette 
Polystyrene tubes (BD Falcon, 352058) 
 
A6.2 Procedure 
 
1. Wash cells in ice cold stain buffer and resuspend each sample at a concentration of 106 cells/50 
µl stain buffer.  
 
2. Pipet 50 µl of cell suspension into a well of a 96-well non-TC U-bottom plate. Keep plate on ice 
during entire staining protocol. 
  
3. For each sample being stained with antibodies, add 0.5-1 µg FC block in 10 µl stain buffer (pipet 
up and down to mix). Add 10 µl to each well being stained and incubate on ice for 15 minutes. In 
the meantime, prepare the staining antibodies (see step 4). 
 
4. Since the cells are already in a 60 µl volume, prepare multi-stains, single stains, and isotype 
controls in stain buffer so that when 40 µl is added to each well, the final concentration equals 
the highest recommended concentration by the manufacturer for 106 cells in a 100 µl volume. 
 
5. After the FC blocking step, add 40 µl of staining or isotype antibody to each well (pipet up and 
down to mix) and incubate on ice for 30 minutes. Protect from light. 
 
6. Wash wells by pipetting an additional 100 µl stain buffer using a multichannel pipette. Spin plate 
at 1200 RPM (~300 RCF) for 5 minutes and flick plate into sink to remove supernatant. Wash 
cells 2 more times as above with 200 µl stain buffer. 
 
7. After the last wash, resuspend cells in 200 µl stain buffer and add to a polystyrene tube 
containing 300 µl stain buffer.  
 
8. Keep cells on ice or at 4°C until analysis and protect from light. If staining is being done on a 
different day, you can resuspend cells in 0.1% PFA in PBS instead.  
